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Abstract
The Development of a Medical
Biomarker Test to Aid in Rapid
Screening for the Presence of
Infectious Diseases
DJ Bradford
Department of Mechanical and Mechatronic Engineering,
University of Stellenbosch,
Private bag X1, Matieland 7602.
Research assignment: Masters Thesis
April 2019
The widespread threat of antimicrobial resistance poses a major problem world-
wide. A low-cost rapid biomarker test to aid in the screening of infectious diseases
could potentially play a major role in promoting antimicrobial stewardship, thus
combating antimicrobial resistance. Here, the prototype development of such a
test is reported. C-reactive protein (CRP) and procalcitonin (PCT) were the cho-
sen biomarkers for the test, based on recommendations from literature. Organic
electrochemical transistors (OECTs) were chosen for the sensing platform, and
were subsequently designed and fabricated using a desktop inkjet printer. The
OECT was made sensitive to the target biomarkers by immobilising antibodies,
as biorecognition elements, onto the sensor surface. The sensor was then char-
acterised and tested using a National Instruments data acquisition device (DAQ)
controlled by a series of LabVIEW programs. The CRP sensors displayed sensi-
tivity to CRP concentrations between 0.3125 µg/mL and 10 µg/mL, whilst the
PCT sensors showed no discernible response to the PCT protein. Further work
is recommended to enable exact quantiﬁcation of CRP concentrations, as well as
enable the correct detection of PCT proteins.
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Uittreksel
The Development of a Medical
Biomarker Test to Aid in Rapid
Screening for the Presence of
Infectious Diseases
DJ Bradford
Department of Mechanical and Mechatronic Engineering,
University of Stellenbosch,
Private bag X1, Matieland 7602.
Navorsingswerkstuk: Masters Thesis
April 2019
Wydverspreide antimikrobiese weerstand is 'n wêreldwye probleem. 'n Goedkoop,
vinnige biomerker toets, om te help met die sifting van aansteeklike siektes, kan
dus 'n groot rol in die bevordering van antimikrobiese weerstand speel. In hierdie
studie word die ontwikkeling van so 'n prototiepe aangemeld. C-reactive protein
(CRP) en procalcitonin (PCT) is gekies as biomerkers na aanleiding van aanbeve-
lings vanuit die literatuur studie. Organiese elekrochemiese transistors (OECTs)
is gekies vir die sensor platform, en is ontwerp om deur 'n goedkoop huishoudelike
drukker vervaardig te word. Die OECT is sensitief tot die teiken biomerkers by ge-
ïmmobiliseerde teenligaampies as bio-erkenning elemente, op die sensor oppervlak
te gebruik. Die sensor is gekarakteriseer en getoets met 'n National Instruments
(NI) data verkrygings toestel (DAQ) en is gekontroleer deur LabVIEW sagteware.
Die CRP sensors het sensitiwiteit vir CRP konsentrasies tussen 0.3125 µg/mL en
10 µg/mL gewys, terwyl die PCT sensors geen waarneembare reaksie tot PCT
protein gewys het nie. Verdere navorsing om die presiese kwantiﬁsering van CRP
konsentrasies aan te dui en die eﬀektiewe opsporing van PCT proteïne vergemaklik
word aanbeveel.
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Chapter 1
Introduction
1.1 Background
Infectious diseases, such as viral and bacterial infections, present a major health
concern around the world due to their associated high morbidity (condition of be-
ing diseased) and mortality (death) rates [1]. One of the main causes of concern is
the increasing threat of antimicrobial resistance, in which antimicrobial-resistant
bacteria cause various common infections to become increasingly challenging to
treat and take longer to resolve [2; 3; 4; 1]. According to Sambursky et al. [1],
antibiotic-resistant infections contribute almost USD20 billion in excess healthcare
costs, and account for productivity losses of up to USD35 billion every year in the
United States alone.
Antimicrobial-resistant bacteria result from the common overuse, misappropria-
tion and mishandling of antibiotics in the healthcare sector. Reasons for this
misuse include: patients' expectations about the beneﬁts of antibiotic therapy, the
lack of clinically diﬀerentiable features between viral and bacterial infections, the
time pressures associated with diagnosis and treatment [2], and the high costs of
more complex decision systems, such as blood tests [5].
Complex clinical analysis techniques allow physicians access to a broad array of
quantiﬁable markers, known as biomarkers, that can assist in the diagnosis, prog-
nosis and monitoring of infections. Biomarker analyses are generally carried out
by specialised staﬀ in a laboratory setting. Furthermore, they are often removed
from the point-of-care, require expensive equipment, are highly costly and are
time-consuming. In most cases, however, the clinical outcome is dependent on the
speciﬁcity and speed of diagnosis, thus limiting the eﬀectiveness and accessibility
of current test methods.
1
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Therefore, there is great need for a fast, low cost and accessible biomarker test
to aid in the screening of infectious diseases, thus supporting the worldwide eﬀort
of antimicrobial stewardship and combating the imminent threat of antimicrobial
resistance.
1.2 Motivation
According to Sambursky et al. [1], an aﬀordable rapid medical-biomarker testing
device, able to assist in the diﬀerential diagnosis of viral and bacterial infections,
aid in the determination of prognosis, and aid in monitoring of an infection, could
have a profound impact on worldwide healthcare. Use of such a test could impact
the foundational causes of antibiotic misuse, and promote the worldwide steward-
ship of antimicrobials. A rapid medical-biomarker test would allow the physician
to know the value of a speciﬁc biomarker at a given time. Knowing the speciﬁc
value of a medical-biomarker for infectious diseases could:
1. assist physicians in screening for infectious diseases and in the diﬀerentiation
between viral and bacterial infections.
2. enable the early detection of bacterial infections within the critical window
of diagnosis, decreasing the rate of morbidity and mortality associated with
these infections.
3. lead to an improvement in the immune-response of a patient by guiding
the prescription, initiation and termination of antibiotic therapy [2], thus
limiting the overuse of antibiotics.
4. impact physician-patient relationships, allowing physicians, in the case of
viral infection, to reassure patients that antibiotics are not necessary.
5. allow tests to be carried out in any setting, whether it be a rural clinic,
doctor's oﬃce, or even surgical theater, where the decision whether to use
antibiotics may be crucial.
6. be made at low cost, and on a commercial scale, due to the aﬀordability of
newly developed biosensing technologies.
Over the past decade, an array of new biosensors have demonstrated high sensi-
tivity to a large number of microbiological substances, such as protein biomark-
ers, DNA, cells, and ions. Additionally, many of these biosensors have demon-
strated high volume and low cost fabrication methods. The development of a
rapid biomarker test based on new biosensor technology could, therefore, present
an aﬀordable and eﬀective solution.
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1.3 Objectives
The primary objective of the reported project is to develop a rapid biosensor test
to aid in the diagnosis, prognosis and monitoring of infectious disease. The sub-
objectives of the project are:
1. to identify applicable biomarkers that could be used for the screening of
infectious diseases;
2. to identify a rapid and cost eﬀective sensing method for the quantiﬁcation
of these biomarkers;
3. to develop a prototype/proof-of-concept sensor based on the identiﬁed sens-
ing method;
4. to develop a measurement system on which to validate and test the prototype
sensor;
5. to validate and characterise the prototype sensor and its main components;
6. to carry out tests to determine the performance of the sensors in detecting
the relevant biomarkers.
The following report details the development of a rapid biomarker test to aid in the
screening of infectious diseases. The report begins by detailing the comprehensive
literature study conducted to establish the background of the project, assess the
relevant biosensor technologies, and assist in the design, fabrication and testing
of the prototype. Following the literature review, the conceptualisation phase of
the project is described, in which the main subsystems were identiﬁed, relevent
biomarkers chosen, and requirements for each subsystem deﬁned. The design of the
main subsystems and their integration, as well as the veriﬁcation of each respective
subsystem is then outlined. The ﬁnal testing of the proof-of-concept biosensor,
developed as a rapid biomarker test, is described followed by the conclusions and
recommendations in the ﬁnal two chapters.
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Literature Study
The following chapter describes all important literature reviewed during the exe-
cution of the reported project.
2.1 Biomarkers of Infectious Disease
The purpose of the following chapter is to deﬁne and highlight the fundamental
theory behind biomarkers and their use as diagnostic tools, thereafter focusing on
biomarkers speciﬁcally used as tools for the diagnosis of infections.
2.1.1 What is a Biomarker?
In order to discuss the use of biomarkers as diagnostic tools, it is helpful to ﬁrst
adopt a generally accepted deﬁnition of a biomarker. The term "biomarker" is
a portmanteau made up from the combination of the words "biological" and
"marker" [6]. Historically, the term's deﬁnition was surrounded by ambiguity,
stemming from its use in multiple diﬀerent ﬁelds. However, in 1998, the Biomark-
ers Deﬁnition Working Group, was convened by the U.S. National Institutes of
Health (NIH) and U.S. Food and Drug Administration (FDA), in order to im-
prove communication and standardise terminology across all ﬁelds. One of the
outputs developed by the working group is the BEST Resource (Biomarkers, End-
pointS and other Tools), which is comprised of a glossary of terms that "clariﬁes
important deﬁnitions and describes some of the hierarchical relationships, connec-
tions and dependencies among the terms it contains." Furthermore, the intention
of the "BEST Resource" is for professionals and researchers in all ﬁelds to "use the
deﬁnitions included in this glossary when communicating on topics related to its
contents (e.g., biomarkers) to ensure a consistent use of the terms and therefore,
a common understanding of the issues." [7] In the interest of clarity of communi-
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cation and progress, therefore, all terminology relating to "biomarkers" and sub-
sequent deﬁnitions thereof in this document will be aligned with those contained
in the BEST Resource.
According to BEST, a biomarker is described as: "A deﬁned characteristic that
is measured as an indicator of normal biological processes, pathogenic processes,
or responses to an exposure or intervention, including therapeutic interventions.
Molecular, histologic, radiographic, or physiologic characteristics are types of biomark-
ers. A biomarker is not an assessment of how an individual feels, functions, or
survives." [7] In other words, a biomarker is an objectively, accurately and repro-
ducibly measurable characteristic of the human body, which may be molecular,
histologic, radiographic or physiologic in nature, that is directly proportional to
some normal biological process, pathogenic process, or pharmacologic response to
an exposure or intervention (e.g. drugs, surgery, vaccines [8]). Importantly, a
biomarker is a subcategory of medical signs, in contrast to medical symptoms,
which are patient's perceived indications of health or illness [6]. Thus, as stated
in the deﬁnition, biomarkers are not an "assessment of how an individual feels,
functions, or survives", but are rather objective measures of some biological char-
acteristic which may, but do not always, correlate to a patient's sense of wellbeing.
The deﬁnition of a "clinical endpoint" is "a characteristic or variable that reﬂects
how a subject feels, functions or survives" in a study or clinical trial. In other
words, it is a measurement of some disease characteristic that reﬂects the eﬀect of
an intervention [8]. Clinical endpoints have, for a long time, been considered the
primary, and in many cases the only suitable, endpoints of all clinical research.
This is because they are directly concerned with the end goal of clinical research:
to decrease morbidity and mortality [6]. After all, patients themselves are not con-
cerned about a measurable biological characteristic, but are only concerned with
treatment of the disease or illness that this characteristic may reﬂect, to increase
their sense of wellbeing. Thus, the closer the relationship between a biomarker
and a clinical endpoint, the more valuable the biomarker to clinical research.
The highest status that a biomarker can achieve, therefore, is the status of "surro-
gate endpoint". A surrogate endpoint is, as the name suggests, a biomarker that
can serve as a substitute (but not replacement) for a clinical endpoint [6]. The
formal deﬁnition of a surrogate endpoint, taken from BEST, is: "An endpoint that
is used in clinical trials as a substitute for a direct measure of how a patient feels,
functions, or survives. A surrogate endpoint does not measure the clinical beneﬁt
of primary interest in and of itself, but rather is expected to predict that clinical
beneﬁt or harm based on epidemiologic, therapeutic, pathophysiologic, or other
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scientiﬁc evidence." [7] Surrogate endpoints are a subset of biomarkers, and the
use of a biomarker as a surrogate endpoint requires demonstration of its accuracy
(correlation of the biomarker with the endpoint) and precision (the reproducibility
of the measure) [8].
In addition to the four types of biomarkers (molecular, histologic, radiographic
and physiologic), there are seven categories of biomarkers, as shown in table G.1
of appendix G. Of the seven stated categories, four are associated with illness
and disease, and four are associated with exposure to a medical product or an
environmental agent, with the overlap being the monitoring biomarker, which is
associated with the monitoring of either illness and disease or exposure to a medi-
cal product or environmental agent. The four biomarker categories associated with
illness and disease have the most potential for clinical use - each fulﬁlling a diﬀerent
function: susceptibility/ risk biomarkers can be used to assess the potential of a
patient developing an illness or disease, such as identiﬁcation of immunocomprim-
ised/ immunodeﬁcient individuals; diagnostic biomarkers can be used as a tool
for the diagnosis and diﬀerentiation of many diﬀerent types of illness and disease;
monitoring biomarkers can be used to assess the status of an illness or disease; and
prognostic biomarkers can be used to identify the likelihood of the progression of
an illness or disease.
Biomarkers of particular interest are diagnostic, prognostic and monitoring biomark-
ers, speciﬁcally of infection, that give clinicians measurable parameters for the ap-
propriation of antibiotics, and can thus play a key role in reducing the worldwide
problem of antibiotic resistance.
2.1.2 Diagnostic, Prognostic and Monitoring Biomarkers
of Infectious Disease
As mentioned above, the biomarkers of particular interest are diagnostic, prog-
nostic and monitoring biomarkers. Thus, the ideal biomarker of infectious disease
should have diagnostic, prognostic and monitoring characteristics [1] [9]. Its uses
should entail:
1. aiding in the diﬀerentiation between viral and bacterial infections,
2. aiding prognosis,
3. aiding in the monitoring of host response to an infection and antibiotic ther-
apy,
4. guidance in antibiotic therapy [2].
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There is an increasing amount of literature concerned with the pursuit of the do-
it-all biomarker. Some of the most researched biomarkers of infectious diseases
include: C-reactive protein (CRP), serum procalcitonin (PCT), myxovirus resis-
tance protein A (MxA), CD64, erythrocyte sedimentation rate (ESR), interleukin
6 (IL-6), interleukin 8 (IL-8), interferon  gamma (IFN-γ), tumor nectrosis factor
 alpha (TNF-α) and serum amyloid A (SAA) [10; 11; 12; 13; 1].
According to two studies concerned with literature relating to biomarkers as diag-
nostic tools for bacterial infection and sepsis, one conducted by Meem et al. [14]
and the other by Hedegaard et al. [13], two of the most widely researched biomark-
ers for infectious disease are: CRP and PCT. This is due to, amongst others, their
suitability to daily testing (for monitoring purposes), early response to infection
(for early diagnostic purposes), and predictive accuracy of the level of infection
(for prognostic purposes). The following section describes, more speciﬁcally, the
usefulness of CRP and PCT as biomarkers for infectious disease.
2.2 C-Reactive Protein (CRP) and Procalcitonin
(PCT) as Biomarkers of Infection
The following section focuses on the use of C-reactive protein (CRP) and procalci-
tonin (PCT) as biomarkers for infection. It begins with a physiological description
of the two proteins, thereafter outlining how they are used as biomarkers in prac-
tice, and ﬁnally current measurement methods for CRP and PCT.
2.2.1 Description of C-Reactive Protein (CRP) and
Procalcitonin (PCT)
This subsection provides a brief overview of the CRP and PCT proteins, their
basic physiological function and how they are produced.
What is C-Reactive Protein (CRP)?
C-reactive protein (CRP) is a 24 kDa (kilodalton) acute phase protein, with a
half-life of 19 hours, which is commonly used as a general inﬂammation and in-
fection biomarker [15]. Acute phase proteins are plasma proteins, the production
and serum concentrations of which are up-regulated in response to inﬂammation,
infection, cardiovascular disease, cancer and tissue injury [16]. Normal serum con-
centrations of CRP are generally below 3 µg/ml [1] in healthy patients without
any form of infection, inﬂammation or injury. CRP levels, however, have been
reported to rise as high as 500 µg/ml in cases of severe systemic infection.
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CRP levels respond diﬀerently to viral and bacterial infections. Bacterial infection
is a strong stimulus for the elevation of CRP levels, with CRP levels rising cor-
responding to the level of infection, as early as 4 to 6 hours after infection. Peak
CRP levels occur about 36 hours after infection and drop rapidly after antibiotic
therapy [1]. Viral infections do not generally increase the serum concentration of
CRP above 10 µg/ml, with the exceptions of inﬂuenza and invasive adenovirus,
which can yield CRP levels between 10 and 80 µg/ml [17].
The main advantages of CRP as a biomarker for infection are: that it has been
extensively researched and has well deﬁned cut-oﬀ values, it can be used as a
screening method for a wide range of infectious diseases and inﬂammation, and
the diﬀerence in CRP response between viral and bacterial infections (in some
cases) can give an initial indication about the type (viral or bacterial) of the in-
fection.
What is Procalcitonin (PCT)?
Procalcitonin is a 13 kDa, 113-amino acid, polypeptide (proteins are made up of
one or more polypeptide chain) precursor to the calcitonin hormone, and is of-
ten referred to as a "hormokine" [9]. Hormokines, as their names suggest, can
either exhibit hormonal characteristics or, upon inﬂammatory response, can show
cytokine-like behaviour [10]. From the hormonal standpoint, PCT is produced
exclusively by endocrine cells, such as C cells in the thyroid and K cells in the
lungs [11]. The inﬂammatory release of PCT can be induced in two diﬀerent ways:
either directly - through microbial toxins such as endotoxin, or indirectly - through
cell-mediated host response such as tumor nectrosis factor  alpha (TNF-α) and
interleukin 6 (IL-6), amongst others [10]. The physiology behind the production
of PCT after inﬂammation and its function are still reportedly unknown [18].
It has been shown that normal serum concentrations of PCT in a healthy pa-
tient is 0.033 ng/ml, which can elevate up to 5000 times within 2 to 4 hours of
infection, in cases of severe bacterial infection, and these levels persist until recov-
ery [10]. Importantly, PCT levels do not elevate in cases of viral infection, but are
only elevated during bacterial infection.
One of the main advantages of PCT as a biomarker for infectious disease is its
quick response to bacterial infection (early induction time), allowing early diag-
nosis. A second important advantage is its long half-life of 22 to 26 hours, thus
allowing daily measurement, which is essential for monitoring purposes (showing
a patient's response to antibiotic therapy), and its aid in prognosis (the course
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of PCT predicting the risk of mortality in critically ill patients) [9]. Finally, the
ability of PCT to assist in the diﬀerentiation between viral and bacterial infections
is highly advantageous and can play a key role in the appropriation of antibiotics.
2.2.2 Current and Historical uses of CRP and PCT
CRP is one of the most widely used diagnostic and prognostic biomarkers [12], es-
pecially in the emergency room [19], and is often used as a ﬁrst screening method
for suspected bacterial infection [1]. One of the most useful diagnostic traits of
CRP as a biomarker is its ability to assist in the diﬀerentiation between pneu-
monia and acute bronchitis. Studies have shown that CRP levels associated with
pneumonia seldom rise above 10 µg/ml, in comparison to levels above 100 µg/ml
associated with acute bronchitis [12]. Despite, over recent years, receiving much
scrutiny for its lack of speciﬁcity and late appearance, along with other more sensi-
tive and speciﬁc biomarkers for infection being discovered, CRP remains a popular
biomarker and is often used in conjunction with other biomarkers for diagnostic
purposes.
PCT, on the other hand, has received much attention over recent years for its
fast response time, high speciﬁcity (especially to bacterial infections), and long
half-life, thus displaying ideal traits for a diagnostic, monitoring and prognostic
biomarker. Its uses include, amongst others: aiding in the discrimination between
viral and bacterial infections, identiﬁcation of bacterial infection, early diagosis of
sepsis, guidance in antibiotic therapy and the termination thereof, determination
of the eﬀectiveness of antibiotic therapy, and information regarding the extent and
severity of an infection - aiding in prognosis and determining the risk of mortality
[10; 12; 9; 19; 11; 18]. Apart from its well known diagnostic capability, many stud-
ies have shown that PCT is also a highly informative biomarker for monitoring
host response to the infection and treatment thereof. It has been shown that if
PCT levels decrease by 30% of the initial value after 24 hours of antibiotic treat-
ment, the treatment is eﬀective and the infection is under control [18]. Conversely,
an increase in PCT levels indicates that the current antibiotic treatment is not
eﬀective and should be changed.
The cut-oﬀ value for a diagnostic test, in short, is a statistical term that refers
to a threshold value, either a maximum or minimum, which separates a negative
reading from a positive reading. In the case of a biomarker, for example, cut-oﬀ
values are often maximum values, above which, the presence of the biomarker in-
dicates the corresponding presence of a particular condition or disease. There are
many diﬀerent publications on the ideal cut-oﬀ values for CRP and PCT relating
to the diagnosis of infection. Sambursky et al. prescribes CRP diagnostic cut-oﬀ
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Table 2.1: Recommended CRP diagnostic cut-oﬀ values for suspected upper res-
piratory tract infections by Sambursky et al. [1]
Concentration range
(µg/mL)
Diagnostic Indication Antibiotics?
CRP > 60 Highly likely bacterial infection Yes
20 < CRP < 60 Likely bacterial infection Yes
10 < CRP < 20 Likely viral infection No
CRP < 10 Neither viral nor bacterial infection No
Table 2.2: Recommended PCT diagnostic cut-oﬀ values for suspected respiratory
tract infections by Lee et al. [10]
Concentration range
(ng/mL)
Diagnostic Indication Antibiotics?
PCT > 0.5 Highly likely bacterial infection Yes
0.25 < PCT < 0.5 Likely bacterial infection Yes
0.10 < PCT < 0.25 Bacterial infection unlikely No
PCT < 0.10 Bacterial infection highly unlikely No
values for suspected respiratory tract infections as shown in table 2.1. Here, the
recommended cut-oﬀ value for bacterial infection being 20 µg/mL and the cut-oﬀ
value for viral infection being 10 µg/mL. Qu et al. [11] recommend the optimised
CRP cut-oﬀ value for bacterial infection in febrile patients to be 73.8 µg/mL.
Similarly, a study by Lee et al. prescribed PCT cut-oﬀ values for the diagnosis
of respiratory tract infections as shown in table2.2. Here, with the recommended
cut-oﬀ value for bacterial infection being 0.25 ng/mL. Comparatively, both Qu
et al. [11] and Mohan et al. [9] recommend the optimised PCT cut-oﬀ value for
bacterial infection in febrile patients to be 0.26 ng/mL.
2.2.3 The Combination of CRP and PCT in a
Point-Of-Care Rapid Diagnostic Test
Although both CRP and PCT are ubiquitously used to diagnose, monitor and aid
in the prognosis of infections [1], literature suggests that PCT is better than CRP
as a biomarker for infection [11; 12; 9]. Despite this, there is evidence that these
biomarkers on their own lack the speciﬁcity for accurate diagnosis [19]. Further-
more, there is an increasing amount of literature concerned with the multiplexing
of diﬀerent biomarkers to yield better decision making criteria for infections.
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Therefore, the combination of CRP and PCT has been recommended, in liter-
ature, due to increased speciﬁcity and sensitivity in the the diagnosis of infection
[19; 2; 20; 1]. This is especially helpful for the diﬀerentiation between viral and
bacterial infections, which is one of the largest problems facing clinical practition-
ers today, and plays a major role in the prevention of antimicrobial resistance
[11; 1].
2.2.4 Current Measurement of CRP and PCT
Today, CRP and PCT detection and quantiﬁcation are generally carried out on im-
munoassay, in highly regulated lab environments [12]. The most common of which
being Enzyne-Linked Immunosorbent Assay (ELISA) and the Meso Scale Discov-
ery (MSD) - Electrochemiluminescence (ECL) proprietary technology. ELISA,
or more speciﬁcally sandwich-type ELISA, makes use of an antibody-protein-
antibody-enzyme sandwich, whereby the detection of a particular protein and
the subsequent binding of the enzyme-linked secondary antibody to an enzymatic
marker, produces a measurable signal. The signal is generally colorimetric in na-
ture, and is often read by complex lab equipment. MSD is similar to ELISA, for
the most part, but the signal reading in this case makes use of electrochemilumi-
nescence.
In developing countries, which often lack access to proper lab facilities, latex ag-
glutination has been used for the qualitative and semi-quantitative detection of
CRP. Immunoassays, which are the method of choice, however, are seldom avail-
able in these settings. Current measurement methods of CRP and PCT, therefore,
pose large barriers to their use as biomarkers. The main disadvantages of these
methods are that they rely on complex and expensive equipment, require highly
trained lab personnel, are time-consuming, and are highly expensive [9]. In South
Africa, the cost of a standard CRP test is about R171.40 and the cost of a PCT
test is as high as R726.50 [21]. Along with the high cost of these respective tests,
results may only return from the lab between 6 and 48 hours after the request,
by which time the patient's condition may have dramatically worsened. For these
reasons doctors, especially in primary care, often forgo these tests and diagnose
patients according to clinical symptoms alone.
The development of a rapid and cost eﬀective test, for CRP, PCT or the com-
bination thereof, has the potential to have a large impact on developing countries
and the reduction of antibiotic resistance worldwide [1].
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2.3 Biosensors and Biosensing Technology
2.3.1 What is a Biosensor?
A biosensor, as deﬁned by the International Union of Pure and Applied Chemistry
(IUPAC) is "a device which uses speciﬁc biochemical reactions mediated by isolated
enzymes, immunosystems, tissues, organelles or whole cells to detect chemical or
biological compounds, usually by use of electrical, thermo or optical signals" [22].
Put simply, a biosensor is an analytical device that converts the molecular or
biological recognition of a target analyte, into a readable signal via some form
of transducer [23]. Biosensors have been applied in a wide range of industries,
including healthcare, food science and environmental screening [24].
2.3.2 Biosensing Mechanisms and Types of Biosensors
The primary detection strategies used in biosensors for healthcare applications
are optical, mechanical and electrical-based biosensors. This section describes the
basic advantages and disadvantages of each approach.
Optical Biosensors
The main type of optical biosensor is called surface plasmon resonance (SPR),
which relies on the intensity of reﬂected light for detection. SPR allows for real-
time measurement and high throughput [23], but requires costly equipment and
test preparation can be tedious.
Mechanical Biosensors
There are two main types of mechanical-based biosensors, namely microcantilever
(MCL) and quartz crystal microbalance (QCM) [25]. MCLs rely on changes in
mass upon target binding causing deﬂection of the cantilever, whilst QCMs rely
on modiﬁcation of the resonant frequency of an oscillating quartz crystal upon
binding of the target to the surface. Both methods enable real-time detection, but
are highly sensitive to changes in environmental conditions, such as temperature
[23]. They also require complex micro-fabrication techniques.
Electrical Biosensors
Electrical biosensors are by far the most widely researched biosensors due to their
high sensitivity and straightforward integration with electronics. Electrical sensing
methods most commonly employed for healthcare applications are generally based
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on impedance, potentiometric, amperometric , voltammetric, or transistor read-
ings. Among these, transistor-based biosensors have recently become the subject
of much attention, due to multiple demonstrations of the low cost and easily man-
ufacturable subclass of transistors called organic thin-ﬁlm transistors (OTFTs).
OTFT-based biosensors can be easily fabricated and are suitable for mass produc-
tion [26], have simple architectures, are highly biocompatible and have exhibited
high sensitivities in a plethora of biosensing applications. OTFTs, therefore, are
the ideal platform for biosensing applications.
2.4 Organic Thin-Film Transistors (OTFTs) as
Biosensors
A transistor or "transfer resistor", deﬁned by the 1956 Nobel Prize Winners in
Physics, is "a resistor or semiconductor device able to amplify an electrical signal
as it is transferred from the input to the output of the device" [24]. They are
typically three terminal devices made functional by the use of a semiconductor as
the functional active material. The basic function of a transistor is to modulate
or amplify the current between two terminals of the device by controlling the cur-
rent or voltage through the third terminal of the device. This is typically done
by modulating the width of a region in the active material, known as the channel.
The properties of the active material, or semiconductor, are the main variables
that determine the performance characteristics of a particular transistor.
With the advances in material manufacture and processing, a relatively new class
of transistors has emerged, known as organic thin ﬁlm transistors (OTFTs). These
are also three terminal devices, consisting of a drain, source and a gate electrode.
The primary diﬀerence that distinguishes OTFTs from traditional devices is the
semiconductor material and device geometry of OTFTs. Where traditional de-
vices are mainly composed of inorganic semiconductors and have three-dimensional
structures, OTFTs, as their name suggests, are composed of organic semiconduc-
tors and have thin ﬁlm, near two-dimensional, architectures.
Transistors have been implemented in a plethora of diﬀerent sensing applications,
demonstrating high-sensitivity detection of chemicals and biological matter, in-
cluding proteins [27]. One of the main pitfalls of traditional silicon-based tran-
sistors is the combination of their high material and manufacture costs, which
dramatically increases upon miniaturisation. OTFTs have shown many advan-
tages over traditional inorganic transistors, leading to the unprecedented rise of
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disposable OTFT-based chemical and biological sensors [28]. The advantages of
OTFTs and their primary attraction to researchers over recent years are: their
low detection limits, high sensitivity, high selectivity, easy miniaturization and
scalability, good bio-compatibility, low power requirements and simple and low
cost manufacture [29; 30; 26]. Indeed, OTFTs posses incredibly high potential as
disposable biosensors. Other applications of OTFTs include implementation as
memory devices, such as RFID tags [31], incorporation into ﬂexible active matrix
displays [32] for the use in portable electronics.
OTFTs are generally divided into two main subcategories: organic ﬁeld-eﬀect
transistors (OFETs) and organic electrochemical transistors (OECTs), according
to their diﬀerent device architectures and working principles [26].
The following section begins with a description of the organic semiconductors vital
to the operation of OTFTs, followed by a description of each of the four main cat-
egories of OTFTs: Organic Field Eﬀect Transistors (OFETs), Electrolyte-Gated
Organic Electrochemical Transistors (EGOFETS), Ion-Sensitive Organic Field-
Eﬀect Transistors (ISOFETs), and Organic Electrochemical Transistors (OECTs).
This section concludes by describing the primary fabrication techniques of OFETs
found in literature.
2.4.1 Conductive Polymers as Organic Semiconductors
In order to understand OTFTs, it is ﬁrst important to understand the organic
semiconductors which make OTFT technology possible. The discovery of the con-
ductive properties of the iodine-doped polymer, polyacetylene, by Shirakawa et al.
[33] paved the way forward for organic electronics research. Before this discovery,
organic pi-conjugated polymers were considered insulators. Aptly, the discovery
subsequently earned the authors the 2000 Nobel prize in Chemistry for "the dis-
covery and development of conductive polymers". Since then, organic semicon-
ductors, or more speciﬁcally polymer semiconductors (also known as conductive
polymers or CPs), have become attractive alternatives to commercialised inorganic
semiconductors, such as silicon and germanium [26]. An organic semiconductor
generally refers to a material consisting of carbon and hydrogen atoms, with inter-
spersions of heteroatomic functional groups containg oxygen, sulphur or nitrogen,
that displays typical semiconductor properties. In other words, they refer to an
organic material that exhibits conductive properties suﬃcient for the operation
of conventional semiconductor devices such as light emitting diodes (LEDs), solar
cells and transistors [34].
One of the main attractions of organic semiconductors is their customisability,
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both physically and chemically, allowing them to be tailored to meet speciﬁc
design, performance and manufacture requirements [35]. This can be done, for
example, by the manipulation of physical conditions or the addition of speciﬁc
functional groups to the pi-conjugated backbone. This high customisability makes
them more versatile than inorganic semiconductors, allowing for new and novel
devices to be realised using a wide range of manufacturing techniques. Another
advantage of organic semiconductors is their relatively simple processing require-
ments in comparison to inorganic semiconductors, which often require state of the
art machinery contained in a clean environment [26]. The widespread commercial-
isation of organic semiconductors has already been established, from OLED (or-
ganic light emitting diode) television and smartphone displays to the xerographic
process common to any typical photocopy machine [34].
Polymer semiconductors or conductive polymers (CPs) consist of a pi-conjugated
backbone and side chains that can increase their solubility in solvents, a key char-
acteristic that allows them to be processed by many diﬀerent solution-processing
techniques, such as screen printing, inkjet printing and spin-coating [26]. Many
other advantages of CPs have been reported, including their light weight, corrosion
resistance, low cost, and mechanical, electrical, chemical, optical and conducting
properties [36; 37]. Polymer semiconductors can be separated into two diﬀerent
categories: intrinsically conductive polymers and extrinsically conductive poly-
mers. The term 'conductive polymer' generally refers to intrinsically conductive
polymers (ICPs); however, in applications where high metal-like conductivity is
required, extrinsically conductive polymers (ECPs), also known as conductive com-
posites, can be used [38]. ECPs are comprised of conductive metals embedded into
CPs or other polymer matrices, making them conductive. Intrinsically conductive
polymers (ICPs) are conductive due to conjugation in the backbone of the polymer
allowing the ﬂow of electronic charge [39].
ICPs are generally of far more interest to researchers due to their suitability to
many diﬀerent applications. ICPs perform particularly well where wet processabil-
ity, high transparency, high ﬂexibility, high bio-compatibility and good conductiv-
ity are required [38; 36]. Conduction due to conjugation in the backbone happens
as a result of pi-conjugation, and can be increased by the addition of dopant species
[40]. Conduction due to pi-conjugation is inherent to the polymer itself, speciﬁcally
to polymers containing double bonds and lone pairs of electrons.
The conductivity of a CP can be increased by doping. Doping refers to either the
reduction or oxidation of a pi-conjugated CP [37]. The oxidation of a pi-conjugated
system results in a p-doped semiconductor; this occurs by exposing a CP to P-
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type dopants, or electron-deﬁcient species. Conversely, reduction of a pi-conjugated
system forms an n-doped semiconductor, which occurs by exposing the polymer
to n-type dopants, or electron-rich species. CPs in which only pi-conjugation is
present, generally have fairly low conductivities, therefore, it is often necessary to
increase their conductivities through doping, especially for transistor-based appli-
cations. This doping is mostly achieved electrochemically, and enhances electron
transfer, ion mobility within the polymer and the ion-exchange properties of the
polymer [36].
High performance organic thin ﬁlm transistors, which fundamentally rely on these
organic semiconductors (or more speciﬁcally conductive polymers), have been
made realisable with the increase in customisable, high performance conductive
polymers. This has led to an increase in the amount of OTFT-related research
over recent years, especially OTFT-based biosensors.
OTFT-based biosensors require organic semiconductors with high conductivity,
resistance to operation in aqueous mediums, good bio-compatibility and that
are solution processable. Diﬀerent doped ICPs tailored by the addition of side
chains and functional groups have been developed for use in OTFT applications.
The most common ICPs that have been implemented in OTFT-based biosensor
applications are Poly(3-hexylthiophene) (P3HT), poly(3-alkylthiophene) (P3AT),
poly(3,4-ethylenedioxythiophene):poly(styrene sulphate) (PEDOT:PSS), poly(3,4-
ethylenedioxythiophene):p-toluenesulphonate (PEDOT:TOS), and pentacene [26;
28]. These ICPs generally ﬁt the requirements of OTFT-based biosensors as men-
tioned above.
The most common conductive polymers of the ones mentioned above are PE-
DOT:PSS and P3HT. P3HT has mostly been implemented in OFET-based chem-
ical and biological sensors, such as pH, ion, DNA and cell sensors, due to its high
carrier mobility [26]. PEDOT:PSS has been implemented mostly in OECT-based
sensors due to its ion-permeability and good performance in aqueous solutions.
PEDOT:PSS is also one of the only conductive polymers available commercially
tailored for the use as an ink, ideal for printing applications.
2.4.2 Organic Field-Eﬀect Transistors (OFETs)
OFETs are made up of similar components to their inorganic counterparts, such
as MOSFETs. That is, they are comprised of three electrodes: the source, drain
and gate, a gate insulator or dielectric layer, and a semiconductor. The distinct
diﬀerence between OFETs and conventional FETs is the choice of semiconductor
and device geometry. The conventional inorganic semiconductor is replaced by
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an organic semiconductor, and the device takes on a two-dimensional, thin-ﬁlm,
geometry. Thus, each component of an OFET (being a subcategory of OTFTs)
is comprised of a thin ﬁlm deposited onto a substrate, by one of a variety of
deposition techniques. Figure 2.1 shows the typical layered structure of an OFET.
The gate of an OFET is separated from the semiconductor by a gate insulator or
dielectric layer. This layer may be made of diﬀerent materials including a vacuum,
polymers and oxides, as used in MOSFETs [28]. The organic semiconductor layer
is connected to the insulating layer, this is known as the semiconductor-insulator
interface. The grain boundaries of the semiconductor-insulator interface are of
particular importance since the active channel is located in this region. Finally,
the source and drain electrodes are in contact with the organic semiconductor layer
and they form connection points between the transistor and external circuitry.
Figure 2.1: Schematic illustration of a typical thin-ﬁlm OFET. Adapted from own
understanding and Kergoat et al. [28].
OFET Working Principle
The working principle of an OFET is based on controlling the density of elec-
tronic carriers in the semiconductor, at the semiconductor-insulator boundary, by
an electric ﬁeld [26]. The electric ﬁeld is caused by the application of a voltage at
the gate electrode. An increase in the density of the majority charge carrier in the
semiconductor causes a channel to open between the source and drain electrodes,
allowing charge to ﬂow. The current through this channel is highly controllable
and can be controlled over a broad range of values via the gate voltage. This be-
haviour is indicative of that of an ampliﬁer. The device also shows characteristics of
a sensor, where changes in gate voltage can cause a change in the channel current.
The operation of a p-channel OFET is shown in ﬁgure 2.2. A p-channel transistor
refers to a device with a p-doped semiconductor. That is, a semiconductor with
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(a) Upon application of a negative gate voltage, the accumulation of
negative charge at the gate-insulator interface causes the accumulation
of positive charge carriers at the semiconductor-insulator interface, via
an electric ﬁeld.
(b) With the channel in place, applying a voltage between the source
and drain electrodes causes charge to ﬂow in the channel.
Figure 2.2: Schematic illustration of the working principle of an OFET. Adapted
from own understanding and Costelloe et al. [4].
excess positive charge carriers, or holes. In a p-channel OFET, upon the applica-
tion of a negative voltage at the gate, free holes in the semiconductor gather at the
semiconductor-insulator interface. This happens in compensation for the negative
charge at the gate-insulator interface. The collection of positive charge carriers at
the semiconductor-insulator interface forms a conductive channel, which is usually
referred to as the active channel. With the conducting channel in place due to the
gate voltage, application of a negative voltage between the source and drain causes
holes to be "injected" into the channel at the source electrode. These holes ﬂow
through the channel and exit at the drain electrode, thus creating an electronic
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current between the source and drain electrodes. The drain current, controlled
in this process of ﬁeld-eﬀect doping, can be described by the well-documented
equations given in equations 2.1 and 2.2 citepLiao2013.
ID =
W
L
µCi(Vg − Vt − VDS
2
) for VDS  Vg − Vt, (2.1)
ID =
W
2L
µCi(Vg − Vt)2 for VDS > Vg − Vt (2.2)
where ID is the current ﬂowing in the active channel between the source and drain
electrodes; W and L are the width and length of the channel respectively; µ is the
mobility of the majority carrier; Ci is the capacitance of the gate insulator; Vg is
the gate voltage; Vt is the threshold voltage, and VDS is the applied voltage across
the drain and source electrodes.
OFET-based Biosensors
OFETs have been implemented in a vast array of sensing applications, typically
operating in aqueous media. Their applications include chemical sensors, able to
detect pH levels, ion concentrations and other chemicals in aqueous media; as well
as biosensors, able to detect diﬀerent bio-species such as proteins and DNA in
aqueous media. The conﬁguration of an OFET sensor is identical to that shown
in ﬁgure 2.1, with the exception of the semiconductor layer being exposed to the
target analyte. OFET sensors are able to detect the properties of target analytes
due to physical and chemical changes of the active layer upon exposure to the an-
alyte. The performance of an OFET is highly dependent on the grain boundaries
at the semiconductor-analyte interface. This change in the physical and chemical
properties at the grain boundaries can often be measured, which is the primary
sensing mechanism of OFET sensors. More speciﬁcally, from equations 2.1 and
2.2, the channel current, ID, can be controlled by the carrier mobility (µ), and
the threshold voltage (Vt), both of which important in sensing applications [26].
The carrier mobility is typically inﬂuenced by the change of surface topography
at the semiconductor-analyte interface when the OFET is exposed to an analyte.
Upon exposure, molecules from the analyte diﬀuse into the semiconductor at the
grain boundaries, thus altering the surface interface [41]. The threshold voltage is
changed due to the doping eﬀect when the OFET is exposed to a target analyte,
as a result of a change in the density of majority carriers in the semiconductor [42].
This is one of the properties that makes OFETs well suited to sensing applications
[28].
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The classic OFET, as described above, has been further optimised into two,
more convenient and sensitive, conﬁgurations speciﬁcally for sensing applications.
These are known as the Electrolyte-Gated OFET (EGOFET) and the Ion-Sensitive
OFET (ISOFET).
The conﬁguration of EGOFETs is substantially diﬀerent from classic OFETs. An
EGOFET has a similar layout to an OECT, shown in 2.3, in which the gate elec-
trode is separated from the semiconductor layer by an electrolyte, instead of a
dielectric layer [24]. Although EGOFETs are classiﬁed as a type of OFET, there
have been reports that they operate in a similar manner to OECTs (addressed in
section 2.4.3), due to the electrochemical doping of the semiconductor [26]. Wang
et al. [24] and Kergoat et al [28] have suggested that capacitive processes, rather
than electrochemical processes, govern the operation of an EGOFET. According
to [26], further work is needed to classify their working principle. In any case,
the ﬁgure of merit that distinguishes EGOFETs from classic OFETs, is their low
operating voltage in comparison to conventional OFETs (<1 V vs <10 V) [24].
This low voltage operation enables them to work below the electrolysis point of
water and within a safe potential for biological matter, making them suitable for
the detection of biomolecules in aqueous media [28].
ISOFETs are, too, diﬀerent in conﬁguration to the typical OFET. They con-
sist of an insulator deposited onto the semiconductor layer, with an electrolyte
being in contact with the insulator surface and the gate electrode being im-
mersed in the electrolyte. This is the most popular conﬁgurations of OFET-based
biosensors. Here, the detection interface is at the insulator-electrolyte boundary.
Thus, by making the insulator sensitive to speciﬁc biomolecules, the detection of
a vast array of biomolecules is possible [28]. Many ISOFETs make use of poly(3-
hexlythiophene) (P3HT) as the semiconductor layer. This, however, results in the
operating voltage of the ISOFET dramatically increasing, above the point at which
many bio-species, such as proteins, denature. This characteristic thus makes them
unsuitable for most biosensing applications.
2.4.3 Organic Electrochemical Transistors (OECTs)
Organic electrochemical transistors (OECTs) were ﬁrst reported by White et al.
[43] in 1984 and have been researched extensively, especially in recent years, for
their potential application as chemical and biological sensors [29; 44; 45]. OECTs
are three terminal devices, consisting of a source, drain, and gate electrode. How-
ever, as is the case with EGOFETs, the solid-state insulating layer is replaced by
an electrolytic medium (liquid or solid), separating the gate electrode from the
organic semiconductor. The organic semiconductor, to which the source and drain
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electrodes are connected, is generally in the form of a doped conducting polymer,
the most common of which being poly(3,4-ethylenedioxythiophene):poly(styrene
sulphonate) (PEDOT:PSS). The typical layered structure of an OECT, with an
immersed gate electrode, is shown in ﬁgure 2.3a. An alternative, and in many
cases more convenient, layout with the gate in the form of a thin ﬁlm, is given in
ﬁgure 2.3b
(a) The layered structure of a typical OECT with an immersed gate
electrode
(b) A convenient conﬁguration of an OECT with a thin ﬁlm gate elec-
trode
Figure 2.3: Schematic of the two most common layouts of an OECT. Adapted
from own understanding and Kergoat et al. [28].
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OECT Working Principle
The working principle of an OECT, similarly to other transistors, is based on the
modulation of the majority carrier density in the active channel of the semiconduc-
tor or conductive polymer [35]. In an OECT, however, this is done by controlling
the level of ion doping in the conductive polymer. Conductive polymers based
on poly(3,4-ethylenedioxythiophene) (PEDOT) with degenerately doped polyan-
ions such as poly(styrene sulphonate) (PSS) or p-toluenesulphonate (TOS) contain
large anions that compensate for the holes in the p-type polymer. These anions
are ﬁxed (that is, they are not mobile); however, the holes in the p-type material
are mobile and are considered the majority carrier in the active material. The
conductivity of the active channel can be modulated by controlling the electro-
chemical migration of mobile ions between the electrolyte and the polymer [26] via
reversible electrochemical reactions. These reversible electrochemical reactions are
mediated by the voltage at the gate electrode.
OECTs based on PEDOT:PSS or PEDOT:TOS are normally-on devices [28], able
to conduct at zero gate voltage, due to the excess of majority charge carriers
caused by the presence of the large anions PSS or TOS. Thus, there exists a cur-
rent path within the organic semiconductor, dominated by the excess majority
carriers, that allows current ﬂow in any direction between the source and drain
electrode, depending on the direction of potential between the two electrodes.
Upon the application of a positive gate voltage, mobile cations in the electrolyte
are injected into the polymer bulk, compensating for the ﬁxed dopant anions. This
is generally referred to as the "de-doping" of the polymer [29]. The presence of
these cations thus decreases the hole density in the active channel, in turn reducing
the conductivity of the polymer, since ions are less mobile than holes [35; 28; 26].
This, therefore, results in an overall reduced current between the source and drain
electrodes. Thus, the current between two electrodes of the OECT (drain and
source) can be modulated by the voltage at the third electrode (gate), consistent
with the deﬁnition of a transistor. The working principle of an OECT is illustrated
in ﬁgure 2.4, and the output and transfer characteristics of an OECT are given by
ﬁgures 2.5 and 2.6 respectively. Note that current ﬂows between the source and
drain electrodes according to the direction of potential diﬀerence across these two
electrodes.
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(a) Diagram of an OECT showing the excess of majority carriers (holes)
along with the ﬁxed dopant anions, in the absence of a gate voltage.
This results in the "normally-on" nature of many OECTs.
(b) The application of a positive voltage at the gate electrode of an
OECT, causing the eﬀective "de-doping" of the polymer as a result of
the injection of positive ions from the electrolyte into the polymer.
Figure 2.4: Simple illustration of the working principle of a typical OECT. Adapted
from own understanding and Costelloe et al. [4].
Figure 2.5: Example of the output characteristics of an OECT for forward and
backward drain voltage sweeps. Reproduced from Macchia et al. [46].
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Figure 2.6: Example transfer characteristics of an OECT. Reproduced from Fad-
doul et al. [47].
At a low source-drain voltage, upon the application of an eﬀective gate voltage, the
current in the active channel of an OECT is directly proportional to the density
of majority carrier in the channel. An estimate of the channel current can then be
given by equation 2.3 [48; 49].
IDS =
qµp0tW
LVP
(VP − V effg +
VDS
2
)VDS for | VDS || VP − V effg | (2.3)
VP =
qp0t
Ci
(2.4)
V effg = VG + Voffset (2.5)
where VP is the pinch-oﬀ voltage; V
eff
G is the eﬀective gate voltage; q is the electric
charge; µ is the hole mobility; p0 is the initial hole density in the active layer in
the absence of an applied gate voltage; t is the thickness of the active layer (con-
ductive polymer or semiconductor); W and L are the channel width and length
respectively; Ci is the eﬀective gate capacitance of the transistor; and Voffset is the
oﬀset voltage which is determined by the drop in potential at the gate-electrolyte
interface and the electrolyte-channel interface [45; 26].
The OECT can be described by two circuits, an electronic circuit and an ionic
circuit. The ﬂow of holes in the active material between the source and drain
electrodes being the electronic circuit, and the ﬂow of ions between the electrolyte
and active material across the electrolyte-semiconductor interface being the ionic
circuit. Since hole transport is far more rapid than ion transport, the response is
limited and highly dominated by the diﬀusion of ions in the ionic circuit under an
applied gate voltage [44; 26].
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The above-mentioned properties of OECTs make them ideal candidates for biosens-
ing applications - wherein their real potential lies.
OECT-based Biosensors
Over recent years, as researchers have begun to unlock their potential, OECTs
have fast become the new 'darling' of the biosensing world. To begin with, their
inherent operation in aqueous electrolytes, converting an ionic current into an elec-
tronic one, provides a simple way to interface biological systems with electronics
[45; 35; 50; 51; 44]. This property is essential to real-time biosensing applications
[26], since the analyte such as serum or whole blood, can serve the additional
function of the acting electrolyte. This stands in contrast to OFET-based sensors,
which are not necessarily tailored for operation in electrolytes, with the excep-
tion of EGOFETs and ISOFETs. Additionally, OECTs operate under very low
voltages, generally below 1 V, which is a requirement in most biosensing applica-
tions to prevent water hydrolysis and unwanted redox reactions in biomolecules
[27; 28; 26]. This, along with the simple signal readout inherent to OECTs [45],
broadens the variety of peripheral electronics required for sensing applications, al-
lowing simple, low-voltage electronics to be incorporated for voltage supply and
measurement. The use of simple and low cost electronics is particularly ideal for
developing hand-held point-of-care biosensing devices.
Another advantage of OECTs for biosensing applications is their inherent signal
ampliﬁcation [45], leading to higher sensitivity than other electrochemical sens-
ing approaches[50]. This is a desirable characteristic in any sensor, where small
changes in the input signal cause large relative changes in the output signal. It
also eliminates the need for output signal ampliﬁcation using electronic circuitry,
further decreasing the requirement for complex peripherals.
Along with the above-mentioned simple and minimal peripheral circuitry require-
ment, the device architecture of an OECT is also straightforward [45]. In the
absence of an insulating layer, OECTs are comprised of a conducting polymer,
such as PEDOT:PSS, and electrodes made of conductive metal-based materials,
such as silver or gold; thus simplifying their fabrication process, which can be
achieved by low-cost solution-processable deposition methods, such as printing.
Finally, many OECT sensors based on conductive polymers have shown good bio-
compatibility [51], showing little to no toxicity to bio-molecules such as proteins,
antibodies, DNA and living cells. This stands in contrast to traditional inorganic
semiconductor-based transistors, which present high toxicity to bio-molecules.
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The above-mentioned characteristic advantages of OECTs makes them ideally
suited to biosensing applications.
2.4.4 OTFT Fabrication
One of the hallmarks of OTFTs is their low cost and easy manufacturability, ow-
ing to their simple structures and the wet solution processibility of their active
materials - organic semiconductors in the form of conductive polymers. The man-
ufacture of OFET devices consists of the deposition of thin layers of material onto
a particular substrate, and in some cases the curing of these materials.
There are several well-established low cost deposition techniques that have been
applied to OTFT fabrication, including vacuum thermal evaporation, spin coat-
ing, and inkjet printing, amongst others. These techniques diﬀer tremendously
and their use is dependent on application.
Vacuum Thermal Evaporation
In this process, both the semiconductor material as well as the substrate are placed
in a vacuum. The organic semiconductor is then thermally heated until the point
of sublimation, upon which it is then condensed to form a thin layer on the surface
of the substrate, which is kept at a low temperature [24]. The main disadvantage of
this process is that the deposition is not easily patterned, and is thus only suitable
for the deposition of the organic semiconductor, with an additional process being
required for the deposition of the patterned electrodes of the OTFT.
Spin Coating
Spin coating is a well known coating process used in many laboratories to achieve
an evenly deposited layer of material onto a substrate. It consists of spinning
a substrate and dripping the coating material in the center of the spinning sub-
strate. The coating material is evenly spread over the substrate under centrifugal
force. The main variables controlling the layer thickness of the deposited layer are
the centrifugal force (controlled by the rotational speed) and the viscosity of the
coating solution [24]. The coating solution is required to be diluted with a solvent
which, during the coating process is evaporated, leaving the coated substrate. Just
as it is the case with thermal evaporation, this process does not allow for pattern
coating, but rather the coating of the entire substrate with a thin layer of the
coating solution. This limits spin coating to the deposition of the organic semi-
conductor layer only, and the patterned electrodes of OTFT devices need to be
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deposited using another technique. Additionally, an extra annealing step is often
required to ensure the crystallisation of the organic semiconductor molecules and
increase its conductivity [52; 53].
An advantage of this method over thermal deposition is that the organic semi-
conductor does not need to be heated, preventing its thermal degradation [24].
Another advantage of the spin coating process is that it is highly accessible, due to
its simplicity. One drawback of this process is that not all organic semiconductors
are able to dissolve in solvents.
Inkjet Printing
Inkjet printing is a well known and widespread solution process used for the depo-
sition of inks in speciﬁc patterns onto a substrate. In some cases, patterning with a
lateral resolution of up to 5 µm has been achieved using this technique [54]. Inkjet
printing provides a cost eﬀective and eﬃcient alternative to lithographic pattern-
ing, and allows materials to be deposited on ﬂexible, lightweight substrates, such
as paper. It has the additional advantage of being an additive process as opposed
to a subtractive process, such as lithography, which ensures less wastage of mate-
rials [24].
This has become a popular method for the fabrication of OTFTs due to the
fact that both the patterned electrodes and the organic semiconductor can be
deposited with high accuracy and repeatability, in the same process. Indeed, by
ﬁlling separate ink cartridges with the relevant material (one with the electrode
material, and the other with the organic semiconductor), it is possible to print
the patterned electrodes followed by the organic semiconductor layer in the same
print cycle. Furthermore, there are commercially available conductive inks, based
both on conductive polymers (speciﬁcally PEDOT:PSS), and metals (such as sil-
ver nano-particle-based ink). These inks have been speciﬁcally tailored for inkjet
printed electronic applications, and make this technique highly convenient.
2.5 Antibodies and Immunosensors
Many biosensors operate in aqueous analytes, such as whole blood, serum or saliva,
containing millions of diﬀerent biological components. In order to enable the de-
tection of speciﬁc bio-molecules, it is often necessary to capture the molecule of
interest out of the analyte and onto the surface of the sensor. Antibodies can
be used eﬀectively for this purpose and are often referred to as bio-recognition
elements in sensing applications. Sensors employing antibodies as bio-recognition
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elements are referred to as immunosensors.
The following section begins by describing some basic theory necessary to the un-
derstanding of the structure of antibodies and their behaviour. It then outlines the
function of antibodies in immunosensing, speciﬁcally in OTFT-based immunosen-
sors. The section concludes by outlining diﬀerent antibody immobilisation strate-
gies and the labelling or conjugation of antibodies with various materials for signal
ampliﬁcation.
2.5.1 Antibodies
What is an Antibody?
An antibody, also known as an immunoglobulin, is a protein, produced by B cells
in the immune system, that is capable of binding with high speciﬁcity to an anti-
gen [55]. Antigens are typically deﬁned as any substance foreign to the body that
induces an immune response [56], and are often proteins, although they may also
be other bio-molecules. Antibodies are Y-shaped proteins, with two diﬀerent re-
gions known as the constant region and the variable region. The structure of an
antibody is shown in ﬁgure 2.7a.
The constant region of an antibody is the same for each antibody (as its name
suggests), but the variable region of the antibody changes according to the epi-
tope to which that antibody targets.
Epitopes
An epitope, also known as an antigenic determinant, refers to a speciﬁc target
region on the surface of an antigen to which an antibody binds. An illustration
of an antibody binding to a speciﬁc epitope on an antigen is given in ﬁgure 2.7b.
Thus, a protein, for example, may have several diﬀerent epitopes, allowing multiple
diﬀerent antibodies to bind to the same protein, due to the unique antibody-
epitope speciﬁcity.
Antibody Speciﬁcity and Aﬃnity
Antibody speciﬁcity and aﬃnity are important characteristics which describe the
ability of an antibody to bind to a target antigen. As it will be shown in section
2.5.2, these are key characteristics when selecting antibodies for immunosensing
applications. Speciﬁcity refers to the ability of the antibody to bind only with
the target antigen, whilst avoiding the detection of unrelated antigens. Antibody
aﬃnity refers to the strength of the bond between an antibody binding site and the
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(a) Schematic illustration of the structure of an anti-
body or immunoglobulin.
(b) Schematic illustration of the binding of an anti-
body to an antigen at a speciﬁc epitope.
Figure 2.7: Basic Schematic of the structure of an antibody and its binding to an
antigen. Adapted from own understanding and Jung et al. [57].
target antigen. High aﬃnity antibodies bind quickly, with high-strength bonds,
and maintain a stable bond under harsh conditions. High speciﬁcity is crucial in
immunosensing applications in order to ensure that the correct target antigen is
being sensed, whilst high aﬃnity is also crucial to immunosensing since it directly
inﬂuences the sensitivity of an immunosensor.
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Monoclonal vs Polyclonal Antibodies
Polyclonal antibodies represent a collection of antibodies produced by many dif-
ferent B cells that recognise many diﬀerent epitopes on the same target antigen.
By contrast, monoclonal antibodies are a collection of antibodies from the same
B cell, and thus target the same epitope on the same target antigen [55]. The
advantages and disadvantages of monoclonal and polyclonal antibodies are given
in table 2.3.
2.5.2 Immunosensors
An immunosensor describes a subtype of biosensors, namely those that utilise anti-
bodies as their biorecognition elements. The following section is a brief overview of
literature concerned with the basic structure of an immunosensor, organic eletro-
chemical transistor (OECT) based immunosensors, methods of immobilizing anti-
bodies onto sensor substrates and ﬁnally the labelling of antibodies with biocom-
patable materials.
What is an Immunosensor?
As described above, an immunosensor is a subclass of biosensors speciﬁcally con-
cerned with the detection of antigens using antibodies as bio-recognition elements.
The main mechanism of immunosensors, in general, is to take advantage of the
change in signal (e.g. electronic, optical, piezoelectric) due to the formation of the
antibody-antigen complex on the sensor surface [58]. Immunosensors are partic-
ularly useful when quantifying the immune response of a patient to a particular
disease, by measuring well known biomarkers associated with an immune response
[59].
Immunosensors have been demonstrated making use use of two diﬀerent detec-
tion approaches, namely labelled and label-free detection. The label-free approach
relies solely on the antibody-antigen complex causing a readable change in out-
put signal of the immunosensor. By contrast, the labelled approach, also known
as sandwich type immunosensors, consist of a second antibody, conjugated to a
nanoparticle, that binds to a diﬀerent epitope on the antigen. This is illustrated
in ﬁgure 2.8.
In this case, the antibody immobilised on the substrate is referred to as the capture
antibody, and the labelled antibody is known as the detection antibody. In this
conﬁguration, the detection antibody binds with the antigen part of the capture
antibody-antigen complex, thus providing a detectable signal via the conjugated
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Table 2.3: The advantages and disadvantages of monoclonal and polyclonal anti-
bodies (adapted from Paciﬁc Immunology [55])
Monoclonal Antibodies Polyclonal Antibodies
Advantages
Production of large quantities of the
same antibody is possible, with high
homogeneity between batches.
Inexpensive.
High speciﬁcity to epitopes. Far less
chance of cross reactivity.
Stable and relatively unaﬀected by pH
changes.
Can provide better results in assays
requiring the exact quantiﬁcation
of a particular protein level.
High aﬃnity due to binding of multiple
epitopes.
More robust detection due to the
binding of multiple epitopes.
High sensitivity for detecting proteins
and other antigens in low
concentrations, due to the binding of
multiple antibodies to the same
antigen.
Easy storage.
Disadvantages
Signiﬁcantly more expensive than
polyclonal antibodies.
High variability between batches.
More demanding storage conditions.
Less speciﬁc due to the detection of
multiple diﬀerent epitopes, resulting in
a higher chance of cross reactivity
(binding to unrelated antigens).
More sensitive to changes in pH levels.
Less robust for detecting proteins that
may be in a denatured state
and small changes in epitope structure.
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nanoparticles [29]. Nanoparticles have been reported to assist in signal ampliﬁ-
cation [50], catalyse electrochemical reactions, and enhance electron transfer [29].
Common nanoparticles used in biosensing applications include gold nanoparticles
(AuNPs) and horseradish peroxidase (HRP) due to their good biocompatibility.
Gold nanoparticles have the added advantage of having a large surface area.
Figure 2.8: Schematic illustration of a sandwich type immunosensor at molecular
level. Adapted from own understanding.
OECT-based Immunosensors
In OECT sensing applications requiring the quantiﬁcation of a particular protein
concentration in an analyte, the use of antibodies is necessary for the capture and
detection of the target protein. Antibodies have been used in many OECT-based
immunosensor applications. The use of antibodies in OECT sensing applications
has been made possible by the excellent biocompatibility of conductive polymers,
allowing the eﬀective immobilisation of antibodies on the sensor surface [26].
OECTs have been applied as immunosensors for the detection of many diﬀerent
protein biomarkers. Kim et al. [29] demonstrated a sandwich type OECT-based
immunosensor for prostate speciﬁc antigen (PSA), using gold nanoparticles for
signal ampliﬁcation. Here, the performance of the device, shown by the drain
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current, was aﬀected by the binding of PSA to the capture antibodies. The signal
was greatly ampliﬁed by the addition of the detection antibodies labelled with gold
nanoparticles. The calibration curves resulting from sweeping the gate voltage at a
constant drain voltage, for diﬀerent concentrations of PSA, both with and without
gold nanoparticles, is shown in ﬁgure 2.9.
(a) Calibration curve without AuNPs (b) Calibration curve with AuNPs.
Figure 2.9: Calibration curves showing the increase of sensitivity of the OECT-
based immunosensor after the addition of AuNP-labelled detection antibodies.
Reproduced from Kim et al. [29].
From ﬁgure 2.9a, it can be seen that the OECT-based immunosensor detects PSA
successfully down to a concentration of 100 pg/ml. It is further shown in ﬁgure
2.9b that the sensitivity of the immunosensor was dramatically increased by the
addition of the AuNP-conjugated detection antibodies, and the device could then
detect PSA down to a concentration of under 10 pg/ml.
2.5.3 Antibody Immobilization Strategies
In immunosensors, capture antibodies provide the interface between the sensor and
the target protein contained in the analyte. There are several aspects of antibody
immobilisation which aﬀect the ability of the capture antibody to detect a speciﬁc
antigen. These are: antibody denaturing, binding site modiﬁcation, antibody ori-
entation and the space between the bound antibody and the surface of the sensor
[57]. Antibody denaturing refers to changes in the antibody's shape, making it
lose its function. The denaturing of antibodies during or after the immobilisation
step decreases the sensitivity of immunosensors. Antibody modiﬁcation at antigen
binding sites decreases the antibody's ability to bind to antigens. This often occurs
due to random chemical tagging of an antibody. Antibody orientation is one of the
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most important aspects aﬀecting the performance of immunosensors. Correct an-
tibody orientation, with the antigen binding sites exposed to the analyte, increases
the antigen binding ability of the immobilised antibodies. It has been shown that
randomly-coupled antibodies exhibit three-times less binding capacity compared
to well-oriented antibodies [60; 57]. Finally, the space between the immobilised
antibody and the surface to which it is immobilised has been shown to play a role
in the eﬀectiveness of antigen binding. Antibodies bound to a solid surface via a
long linking molecule have shown greater binding capabilities [57].
Multiple studies have shown that optimised antibody immobilisation increases
the sensing capability of immunosensors [57; 61; 62]. There are several diﬀerent
methods that have been used for antibody immobilisation onto sensor surfaces.
Four of these are: adsorption, covalent immobilisation, biotin-streptavidin aﬃnity
and antibody-binding proteins.
Adsorption
Antibody adsorption refers to the interaction between an antibody itself and the
surface, in the absence of any other molecules. It occurs by hydrophobic and hy-
drophilic interactions between the antibodies and the surface [57], and is achieved
by incubation of the solid surface in an aqueous medium containing the antibodies.
Adsorption is by far the simplest form of immobilisation since it is a single-step
process and requires no additional antibody modiﬁcation or additional substances.
A disadvantage of this method is that it does not guarantee antibody orientation
and in many cases the antibodies lose functionality of their binding sites due to
denaturing. Furthermore, adsorbed antibodies form a relatively weak bond (and
can be easily detached in harsh conditions, such as washing), and bond directly to
the surface, decreasing the their antigen-binding capabilities.
Covalent Immobilisation
The covalent bonding of antibodies to a surface is also referred to as cross-linking,
and is a common method of antibody immobilisation in immunosensor applica-
tions. This method is popular due to the strong and robust covalent bond formed
between the antibody and a treated surface. In this method, amino groups on
the antibody surface can be coupled with reactive substances coated on the solid
surface to which the antibody is immobilised [57; 61]. The advantages of covalent
immobilisation include: its simplicity, its short process, the well established chem-
istry for surface activation, no denaturing or binding-site modiﬁcation, and the
ability to use long linking molecules to space the antibody from the surface. The
main disadvantage of this method is that a covalently-linked antibody, through its
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amino groups, is randomly oriented.
Biotin-Streptavidin Aﬃnity Immobilisation
Another common method for cross-linking makes use of the near-irreversible biotin-
streptavidin reaction. By covalently labelling the antibody with biotin (also known
as biotinylation), and activating the surface with streptavidin, the biotinylated
antibodies can be immobilised on the streptavidin coated surface through the
strongest non-covalent biological interaction known [60; 61]. This method is also
often used in immunoassays, due to its binding eﬃciency, with one strepavidin
molecule binding up to four biotin molecules. The advantages of this method
include the binding eﬃciency, the aﬃnity of the biotin-streptavidin bond, good
orientation, no binding-site modiﬁcation, no denaturing, and the large space be-
tween the antibody and the surface. A disadvantage of this method is that it can
be time-consuming, due to the the antibody requiring modiﬁcation and the surface
requiring activation.
Antibody-binding Proteins
Antibody-binding proteins bind to speciﬁc regions of an antibody. This process is
similar to the cross-linking process, whereby the surface to which the antibody is
being immobilised requires activation, however in this case the surface is coated
with antibody-binding proteins such as protein A and protein G [57]. An advantage
of this method is that correct antibody orientation is guaranteed since the protein
binds to the same region of the antibody repeatedly. Another advantage of this
approach is that the antibody does not require modiﬁcation, and thus maintains
its antigen-binding functionality. The disadvantages of this approach include: the
reduced stability of the immobilisation in comparison to cross-linking, the addi-
tional step of the immobilisation of antibody-binding protein and the unsuitability
for sandwich type sensors.
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Functional Deconstruction and
Design Speciﬁcation
The following chapter begins by reviewing the project problem statement and
developing requirements for the testing system, thereafter describing the basic
overview of the system, describing relevant subsystems and ﬁnally describing broad
design choices relating to those subsystems.
3.1 System Requirements
The title of the project, being the problem statement, is: "The development of a
rapid biomarker test to aid in the diagnosis, prognosis and monitoring of infectious
diseases." Drawing from this and the project objectives, described in section 1.3,
the requirements for the development of the system are:
1. A functioning proof of concept (prototype) that can detect speciﬁc biomarker(s)
of infectious disease, within a clinically relevant range.
2. The time per test should be signiﬁcantly less than those currently used to
test for biomarkers of infectious disease. This is to ensure the usefulness of
the test for aiding in diagnosis, prognosis and monitoring.
3. The cost of each test to be suitable for the daily testing of a patient in
resource-poor settings.
4. The sensor itself should be usable in any setting, without requiring a labo-
ratory: including doctor's rooms, the ICU and rural clinics.
36
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3.2 System Overview and Division of Subsystems
3.2.1 System Overview
The basic layout of a typical electronic sensor-measurement system is made up
of six main components: the target of measurement, an input signal source (ref-
erence signal), a sensor/ transducer stage, an output signal conditioning stage,
output signal measurement, and ﬁnally a signal interpretation stage. These com-
ponents are shown in ﬁgure 3.1. The "target of measurement" refers to a physical
Figure 3.1: The components of a typical measurement setup. Adapted from Figli-
ola and Beasley [63].
property or the presence of a particular substance, to be measured, either directly
or indirectly, by the sensor. The input signal source generates the supply signal to
the sensor. This is also referred to as the reference signal. The sensor/ transducer
refers to the physical element that employs some natural phenomenon to sense
a physical property or the presence of a particular substance, and consequently
turns the sensed information into a detectable signal [63]. Output signal condi-
tioning refers to the modiﬁcation of a signal into desirable magnitude or gets rid
of undesirable signal components. Examples of signal conditioning are ﬁltration
and ampliﬁcation. Signal measurement refers to the storage of the sensed value in
memory. Finally, signal interpretation refers to the processing and display of the
information in a particular format (e.g. graphically).
Adapting the general layout to the case of a biosensor or, more speciﬁcally, an
immunosensor, the layout can be shown by ﬁgure 3.2. Here, the target of mea-
surement is an analyte containing the biomarkers of interest. Furthermore, the
biosensor is functionalised with biorecognition elements that are sensitive to the
biomarkers of interest. In most cases involving biomarkers, these biorecognition
elements are antibodies. As noted in section 2.5.2, biosensors that make use of
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antibodies as biorecognition elements are known as immunosensors. This sub-
class of biosensors exploits the antibody-antigen (immuno) reaction to separate
the antigen, which in this case is the biomarker of interest, from the analyte.
Figure 3.2: Immunosensor-speciﬁc components for the measurement setup.
Adapted from own understanding and Figliola and Beasley [63].
3.2.2 Division into Subsystems
Immunosensors, being highly integrated compact devices, are at the intersection
between biology and biotechnology, electronics, and chemical physics [58]. The
biological species being sensed along with the biorecognition elements falls in the
ﬁeld of biology and biotechnology; the sensor falls in the ﬁeld of chemical physics;
and ﬁnally, the signal measurement and processing falls in the ﬁeld of electron-
ics. It is advantageous, therefore, to divide the system into separate subsystems
according to their respective ﬁelds. This would allow the characterisation and op-
timisation of each subsystem according to criteria speciﬁc to each relevant ﬁeld,
before integrating them to form the complete system. The division of the system
into three main subsystems is shown in ﬁgure 3.3.
The ﬁrst subsystem is comprised of the biorecognition elements of the immunosen-
sor - antibodies. This subsystem has two main functions: 1. to capture the
biomarkers of interest (antigens) from the analyte; 2. to provide a detectable
signal for the sensor (or strictly speaking, transducer) to detect. The second sub-
system is the sensor itself. The function of this subsystem is to detect the signal,
or change in signal, caused by the binding of the biomarkers (antigen). The third
subsystem consists of the electronic components that send/receive signals to/from
the sensor, store measurements and process the data. This subsystem will be
referred to as the measurement system. The function of the measurement is to
provide input signals, read output signals, store these output signals and process
the stored information for display purposes.
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Figure 3.3: System overview showing the three main subsystems: 1. the biorecog-
nition elements; 2. the sensor; 3. the measurement system.
3.2.3 Subsystem Requirements
Subsytsem 1: Biorecognition Elements
As mentioned above, the ﬁrst subsystem involves the biorecognition elements, or
more speciﬁcally the antibodies, for an immunosensor setup. The design of this
subsystem requires knowledge of the physiology of the chosen biomarkers, and of
the respective antibodies, to ensure that the antibody-antigen complex (referred
to in section 2.5) has high binding aﬃnity and that the binding of the antigens
causes the largest possible detectable signal. The requirements of this subsystem
are:
1. to capture as much of the required biomarker from the analyte as possible
and bind it with high aﬃnity.
2. to be speciﬁc to the biomarker and not bind to unrelated molecules.
3. to bind the biomarker in such a way that its presence has the greatest in-
ﬂuence on the surface of the sensor, causing the largest possible detectable
signal.
Subsytsem 2: Sensor
The second subsystem is the sensor, which is to detect a measurable signal upon
binding of the target antigens to the antibodies immobilised to the sensor surface.
The requirements of the sensor are:
1. to be sensitive to the binding of the target antigens.
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2. to be cheap and disposable, suitable for daily use.
3. to be easily manufacturable.
4. to be stable in aqueous environments.
5. to be highly biocompatible - with regards to both materials and operating
conditions.
6. to be suitable for antibody immobilisation.
Subsytsem 3: Measurement System
The measurement subsystem is concerned with the measurement and supply elec-
tronics of the system. The requirements for the design of the measurement sub-
system are:
1. to convert AC and DC digital signals into analogue signals and supply the
analogue signal to the sensor.
2. to control the input signal attributes to the sensor such as DC oﬀset, ampli-
tude, phase, etc.
3. to provide a stable interface with the sensor.
4. to measure and digitally record analogue signals received from the sensor in
high resolution.
5. to display recorded signal data in real time.
6. to be capable of fully characterising the sensor.
3.3 Biomarker Selection
It was noted in section 2.1.2, that the ideal biomarker for infectious disease should:
aid in the diﬀerentiation between viral and bacterial infections, aid in the deter-
mination of prognosis, aid in the monitoring of host response to an infection and
antibiotic therapy, and ﬁnally guide antibiotic therapy. Furthermore, the studies
by Meem et al. [12] and Hedegaard et al. [13] have shown that C-reactive pro-
tein (CRP) and procalcitonin (PCT) are two of the most widely used biomarkers
for infectious disease, since they fulﬁl all of the requirements listed for the ideal
biomarker. Based on the literature described in sections 2.1 and 2.2, C-reactive
protein (CRP) and procalcitonin (PCT) were the chosen biomarkers for the rapid
biomarker test.
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Design Finalisation and
Manufacture
In the previous chapter, the system was divided into three subsystems: 1. the
biorcognition elements; 2. the sensor; 3. the measurement system. The following
chapter details the design, fabrication and ﬁnally integration of each subsystem,
to form the complete system.
4.1 Biorecognition Element Design and Antibody
Selection
The following section describes the design and selection of the main components
of the biorecognition element subsystem.
4.1.1 Biorecognition Element Design
It was shown in section 2.5.2 that there are two main approaches to immunosens-
ing, with regard to the antibody layout, namely the unlabelled and labelled ap-
proaches. Unlabelled immunosensors make sole use of the antibody-antigen bond
to inﬂuence the sensor surface and produce a measurable change in signal. La-
belled immunosensors, also known as sandwich type immunosensors, rely on an
antibody-antigen-antibody-nanoparticle sandwich at the sensor surface to cause
the change in signal.
It was shown that sandwich type immunosensors have yielded higher sensitivi-
ties and detection limits than unlabelled approaches due to signal ampliﬁcation,
mainly caused by the conjugated nanoparticles. It was therefore decided to use
41
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this type of immunosensor design. A schematic of the antibody layout in a sand-
wich type immunosensor is shown in ﬁgure 2.8.
The chosen approach requires a pair of antibodies - one capture antibody and
one detection antibody - that bind to diﬀerent epitopes on the antigen. The cap-
ture antibody is required to be immobilised on the sensor surface and the detection
antibody requires labelling with a nanoparticle.
Capture Antibody Immobilisation
It has been shown that optimised capture antibody immobilisation plays an essen-
tial role in increasing the performance of immunosensors, as described in section
2.5.3. Of the four methods described in section 2.5.3: adsorption, covalent immo-
bilisation (cross-linking), biotin-streptavidin aﬃnity immobilisation and antibody-
binding proteins, the two methods showing the most promise for this application
are cross-linking and biotin-streptavidin aﬃnity immobilisation. Adsorption, al-
though having the advantage of being simple and requiring no additional sub-
stances, does not guarantee a strong bond with the surface, does not guarantee
antibody orientation, and poses the risk of antibody denaturing, thus negatively
aﬀecting the performance of the sensor. Antibody-binding protein immobilisation,
although holding much potential, is ruled out due to the unsuitability to use in
sandwich type immunosensors.
Both cross-linking and biotin-streptavidin aﬃnity immobilisation have the advan-
tages of no denaturing of the antibody, no binding site modiﬁcation and linking
molecules acting as spacers between the antibody and the sensor surface. Cross-
linking has the added advantage of the formation of a strong, covalent, bond be-
tween the antibody and the surface. On the other hand, biotin-streptavidin aﬃnity
immobilisation has the advantages of good binding eﬃciency, with one streptavidin
molecule binding up to four biotinylated antibodies; and importantly, good anti-
body orientation, increasing the antigen-binding eﬀectiveness up to three times.
Good antibody orientation and high binding eﬃciency are more valuable in im-
munosensor applications than the covalent bond presented by cross-linking, there-
fore, biotin-streptavidin aﬃnity binding was the chosen immobilisation method.
An additional step is often included in the antibody immobilisation step, known
as blocking. This is the process of blocking all binding sites after immobilisation,
in order to ensure that no non-speciﬁc binding takes place when attempting to
sense the target antigens, in this case CRP and PCT. Non-speciﬁc binding occurs
when unrelated biomolecules bind to the surface of a sensor at binding sites, in this
case the streptavidin binding sites and gaps in the streptavidin coating surface,
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exposed after the immobilisation of antibodies. Blocking is usually accomplished
by incubating an already immobilised surface with bovine-serum albumin (BSA)
over a short time period. Therefore, the choice was made to include a blocking
step after antibody immobilisation.
Detection Antibody - Nanoparticle Label Selection
The function of the nanoparticle label is to assist in signal ampliﬁcation by en-
hancing the eﬀect of the biomolecule complex, after binding of the antigen, on the
surface of the sensor. Nanoparticles have also been reported to enhance electron
transfer, and catalyse electrochemical reactions, as noted in section 2.5.2. Amongst
the plethora of nanoparticles, gold nanoparticles (AuNPs) and horeseradish per-
oxidase (HRP) nanoparticles have shown the most promise in immunosensing ap-
plications due to their biocompatibility. HRP is mainly used when the sensing
mechanism requires an electrochemical catalyst upon binding of the target anti-
gen and subsequent binding of the labelled detection antibody. AuNPs are more
generally used due to their large surface area, which increases the "presence" of
the detected antigen upon binding of the AuNP-labelled detection antibody. Many
studies have demonstrated the large increase in sensitivity when using AuNPs for
signal ampliﬁcation, as shown in ﬁgure 2.9.
AuNPs were selected as the chosen detection antibody nanoparticle label due to
the large array of evidence claiming an increase in sensitivity of an immunosensor
when using AuNP-labelled detection antibodies.
Biorecognition Element Layout
According to the design choices made above, the layout of the biorecognition ele-
ments for the immunosensor are shown in ﬁgure 4.1.
4.1.2 Antibody Selection and Ordering
The sensitivity and speciﬁcity of a capture-detection antibody pair cannot be
known before being tested together experimentally by immunoassay. Therefore,
the goal of the antibody selection was to order several diﬀerent antibodies for both
CRP and PCT, thereafter testing experimentally, by immunoassay, the diﬀerent
antibody pairings, to ﬁnd the optimal pairing.
Antibodies, however, are highly costly and can only be purchased in small quanti-
ties, limiting the number of diﬀerent antibodies that could be ordered. The factors
that were considered when choosing the antibodies were:
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Figure 4.1: Illustration of the layout of the antibody-antigen-antibody-AuNP com-
plex. Adapted from own understanding.
1. Cost - the combined cost of the antibodies were to stay within budget.
2. Clonality - The capture antibody was to be polyclonal, to ensure the highest
amount of antigen was captured. The detection antibody was to be mon-
oclonal to enhance speciﬁcity and ensure that a single detection antibody
binds to each antigen, for quantiﬁcation purposes (this was noted in section
2.5).
3. Host species - in order to test diﬀerent antibody pairings using immunoas-
say, the requirement was that the capture and detection antibodies be from
diﬀerent host species.
4. Reactivity - all antibodies were to be reactive to human CRP or PCT.
5. Conjugation - all antibodies were to be unconjugated.
6. Application Suitability - all antibodies were to be made for application in
ELISA or Western Blot.
All antibodies, along with CRP and PCT recombinant proteins, biotin, strepta-
vidin and gold nanoparticles, were ordered through Biocom Biotech, and delivered
to Synexa Life Sciences, where the antibody pair tests were scheduled. The list
of ordered antibodies, as well as other biocomponents, is shown in table 4.1, and
the data sheets of the antibodies and proteins used for ﬁnal testing can be found
in appendix A. Four diﬀerent types of antibodies were ordered for CRP - one
polyclonal and three monoclonal. Unfortunately, due to budget restrictions, poly-
cloncal antibodies were not ordered for PCT. Therefore, three diﬀerent types of
monoclonal antibodies, targeting diﬀerent epitopes, were ordered. Additionally,
due to similar factors, insuﬃcient PCT antibodies were ordered to justify testing
each possible conﬁguration during the pair testing. Thus, the PCT antibodies that
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Table 4.1: Table of all biocomponents ordered through Biocom Africa
Name Company Type Price (excl. VAT)
CRP Capture Abcam Polyclonal R7 460.55
CRP Detection 1 BioVision Monoclonal R8 915.63
CRP Detection 2 Abcam Monoclonal R6 740.99
CRP Detection 3 Abnova Monoclonal R11 042.06
PCT Capture 1 GeneTex Monoclonal R10 105.69
PCT Capture 2 Cloud-Clone Monoclonal R6 196.28
PCT Detection Abbexa Monoclonal R13 522.20
Recombinant Human CRP
Protein
Abcam N/A R6 334.72
Recombinant Human PCT
Protein
RayBiotech N/A R8 386.38
AuNP Abcam N/A R6 408.83
LL Biotin Kit Expedeon N/A R5 370.67
Puriﬁed Streptavidin BioLegend N/A R2 472.81
Total R92 956.81
were ordered with the largest quantity were chosen as detection antibodies, whilst
the remaining two were assigned as capture antibodies.
The antibody pairing tests, where the optimal capture-detection antibody pair-
ings were determined by experimentation with immunoassay, are documented in
the validation chapter, section 5.1.
4.2 Sensor Design and Fabrication
The following section begins by describing the choice of sensor technology, there-
after detailing the design, fabrication and iterative optimisation process for the
sensor.
4.2.1 Chosen Sensor Technology
As described in section 2.3, a biosensor uses speciﬁc biological interactions to detect
biological compounds by the use of electrical, thermal or optical signals. Organic
thin-ﬁlm transistors (OTFTs), as a class of biosensors, have shown great promise
as biosensors due to their easy manufacturability, low cost, high sensitivities and
good biocompatibility. The two main architectures of OTFTs used for biosensing
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applications are organic ﬁeld-eﬀect transistors (OFETs) and organic electrochemi-
cal transistors (OECTs), described in detail in sections 2.4.2 and 2.4.3 respectively.
Although both OECTs and OFETs have shown promise as biosensors, OECTs in
particular have shown great performance as immunosensors, with the additional
advantages of inherent signal ampliﬁcation, inherent operation in aqueous elec-
trolytes, simple device architecture, minimal material requirements and straight-
forward miniaturisation. These advantages, along with excellent published reviews
on OECT sensor performance, led to the selection of the OECT architecture for
the sensor design. Furthermore, according to reported literature, the requirements
of the sensor, stated in section 3.2.3, can all be satisﬁed by an OECT sensor.
4.2.2 Chosen Sensor Patterning Method
In order to satisfy the requirements for a cheap, disposable and easily manufac-
turable sensor, an appropriate fabrication method was sought in literature. From
the literature, brieﬂy described in section 2.4.4, inkjet printing was identiﬁed as
the preferred patterning method for the fabrication of many OECT-based biosen-
sors, even on commercial scale. The only requirement for this method is that the
choice of electrode material and organic semiconductor be solution processable.
The advantages of inkjet printing are that it is an easily accessible technology,
there are many commercially available conductive and semiconductor inks, the
substrate (any type of gloss or photo paper) is cheap and readily available, paper
is easily disposable, patterning to a relatively high resolution is possible, it is a
high throughput process and it is straightforward. Furthermore, Retief et al. [64]
of the SAND group in Stellenbosch University, modiﬁed a desktop inkjet printer
as a low-cost material deposition device, for applications speciﬁcally related to
organic electronics. For the advantages listed above and the convenience of having
it readily available, inkjet printing was the chosen patterning technique.
4.2.3 Chosen Sensor Materials
As shown in the OECT architecture, the most basic components of an OECT are:
the drain, source and gate electrodes, the semiconductor material, the substrate,
and the electrolyte. The main requirement of these materials, apart from the
electrolyte, are that they are stable in aqueous conditions and that they are suitable
for inkjet printing.
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Electrode Material
A solution processable conductive ink was required for the electrode material. Sil-
ver nanoparticle ink, especially developed for inkjet printing of thin-ﬁlm organic
electronic circuitry, already showed good performance when printed on the mod-
iﬁed desktop inkjet printer. This ink, similar to many diﬀerent conductive inks,
requires an additional baking step, in an oven at 100 degrees Celsius for one hour,
to ensure correct sintering of the nanoparticles. Despite this additional step, due
to its availability, this ink was chosen for the electrode material of the OECT.
Semiconductor Material
The list of semiconductor materials that were suitable to application in the sen-
sor were narrowed down into those that were commercially available for solution
processing techniques. PEDOT:PSS was the favoured semiconductor for OECT
applications in literature, and has is also available in aqueous form speciﬁcally for
solution processing purposes. Furthermore, as noted in section 2.4.3, PEDOT:PSS
based OECTs are highly biocompatible since they are normally-on devices, allow-
ing low voltage operation. For the reasons mentioned above, PEDOT:PSS was the
selected as the choice semiconductor.
Substrate Material
Materials that were considered for the substrate on which to print the sensor
included diﬀerent types of paper, polymers, plastic ﬁlms and glass. The require-
ment for the sensor to be low cost and easily manufacturable narrowed the search
down to paper only, since paper is the cheapest and most widely available of the
aforementioned options. The additional requirement that the sensor be stable
in aqueous conditions further narrowed the list of applicable paper types to those
that showed improved water resistance. This would also ensure that the electrodes
remain in a thin ﬁlm on the surface of the substrate, instead of seeping into the
paper and potentially causing a short-circuit.
The three paper types that were considered for the sensor substrate were: 1.
Mitsubishi paper - especially designed for printed electronics, 2. Ultra gloss pa-
per - designed for photo printing, 3. Waterproof paper - also designed for photo
printing. Two tests were done to assess the performance of the diﬀerent paper
types. The ﬁrst test entailed printing silver nanoparticle ink onto each of the three
paper types, and subsequent baking at 100 degree Celsius, to assess their general
print quality, resolution and series resistance. The second test entailed dropping
a single water droplet on the surface of the paper and observing the water resis-
tance of the paper. The results of the ﬁrst test showed that the ultragloss paper
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 4. DESIGN FINALISATION AND MANUFACTURE 48
had the highest print resolution and lowest series resistance, but the silver ink
was easily removed from the surface. The Mitsubishi paper had a slightly lower
print resolution and a slightly higher series resistance, but the silver ink remained
on the surface of the paper more easily. The waterproof paper showed bad print
resolution and high series resistance due to the face that the silver nanoparticles
could not sinter correctly on its surface. In the second test, the water resistance
of the three paper types were about the same.
Due to its consistent performance in the tests mentioned above, the Mitsubishi
paper was chosen as the sensor substrate.
Choice of Electrolyte
In the case of this sensor, and any OECT sensor, the analyte containing the CRP
and PCT proteins can be used as the electrolyte necessary for the operation of the
OECT. It is envisioned that in the future the sensor will operate in serum; however,
for research purposes the use of serum is unnecessary. Phosphate buﬀered saline
(PBS) is a highly biocompatibe electrolyte that is commonly used as a buﬀer for
biological substances. All OECTs, including OECT-based immunosensors found
in literature, made use of PBS as the electrolyte. Furthermore, immunoassays such
as ELISA and MSD make use of PBS as the analyte buﬀer. Therefore, PBS was
the chosen electrolyte (and analyte) for both OECT characterisation (no added
proteins) and for sensing purposes (CRP and PCT added to PBS).
4.2.4 Iterative Sensor Design and Optimisation
The sensor design process began with the sensor requirements (stated in section
3.2.3) as well as the basic OECT architecture (shown in ﬁgures 2.3a and 2.3b) in
mind, and was concerned with developing and characterising a working OECT.
This process, being iterative, was extremely lengthy, with over 300 diﬀerent proto-
types being tested before arriving at a working OECT prototype. For the sake of
brevity, the four most important iterations of the design process will be described.
Additionally, it should be noted that the measurement system, described in section
4.3, was used to characterise the diﬀerent OECT design iterations.
Iteration 1: All Printed OECT Layout
The ﬁrst iteration describes the initial OECT design, comprised of electrodes and a
semiconductor printed directly onto the substrate, based on the architecture shown
in ﬁgure 2.3b. Here, the electrodes were ﬁrst printed onto the paper, followed by
the printing of three PEDOT:PSS layers and baking at 100 degrees Celsius for one
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hour. In order to test the eﬀect of diﬀerent parameters on transistor performance,
diﬀerent electrode patterns were designed in GIMP (GNU Image Manipulation
Program) [65], an open-source raster graphics editor, and subsequently tested.
Testing the output characteristics of the diﬀerent conﬁgurations yielded similar
results for each conﬁguration: the addition of the PBS caused the device to lose
functionality within the ﬁrst minute of the sweep. These results are demonstrated
by ﬁgure C.2 and ﬁgure C.3, where the device clearly ceases to function during
the second gate voltage sweep.
From this point, a single transistor conﬁguration was selected for subsequent op-
timisation, in order to limit variables in the iterative design procedure. Therefore
the sensor conﬁguration anticipated to hold the most promise as a sensor, shown
in ﬁgure 4.2, was chosen. This conﬁguration was chosen due to its anticipated sen-
Figure 4.2: Initial OECT design showing the electrode pattern along with the
PEDOT:PSS semiconductor layer. This conﬁguration has a height of 7.5 mm,
width of 7 mm and a channel width of 100 µm.
sitivity to the addition of the antibodies and proteins, due to its compact shape
and relatively long channel.
Iteration 2: Addition of Photoresist Coating
In the second iteration, an additional step was added to the fabrication process
to improve the stability of the OECT in aqueous conditions and ensure zero PBS
seepage. A method developed by J.D. Retief [64] of the SAND group at Stellen-
bosch University (further described in section 4.4.1), allows the selective coating
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of paper with S1818 photoresist, whilst leaving the printed circuitry and semicon-
ductor uncoated. This method was employed, after the printing of the electrodes
and PEDOT:PSS, to coat the bare paper with photoresist, increasing the stability
of the OECT when immersed in PBS electrolyte. The addition of the photoresist
layer is shown in ﬁgure 4.3.
Figure 4.3: Second OECT design iteration showing the addition of the photoresist
layer in orange.
The example output characteristics given by ﬁgures C.4 and C.5, show that the
OECT had improved endurance, with the photoresist layer increasing the water
resistance of the paper substrate. Despite this, however, the drain current was un-
responsive to changes in supplied gate voltage, decreasing, instead of increasing,
for a negative gate voltage sweep. This behaviour indicated that the OECT dete-
riorated over the sweep time period and that changes in the gate voltage were not
causing a corresponding change in the doping level of the organic semiconductor,
as required. Two further observations were made: the ﬁrst being the oxidation
of the gate electrode at the edge of the PBS droplet, causing the gate electrode
to disconnect from the gate contact pad; the second observation was a noticeable
change in colour of the source electrode as cations penetrated the semiconductor
and ﬂowed in the direction of majority carrier ﬂow.
Iteration 3: Addition of Immersed Gate and Increased Amount of
PEDOT:PSS Layers
The goal of the changes made in the third design iteration were to increase the
eﬀect of the gate voltage on the doping level of the semiconductor, and ensure
the gate electrode did not lose functionality due to oxidation. It was hypothesised
that the decrease in drain current over time was due to both the breakdown of
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the PEDOT:PSS semiconductor, as well as the low anion density, with only three
layers of PEDOT:PSS, causing early semiconductor saturation.
For this iteration, the amount of PEDOT:PSS layers were increased by 5 lay-
ers, to a total of 8 layers, to combat the breakdown of the PEDOT:PSS and to
increase the amount of anions in the active semiconductor ﬁlm. Additionally, the
thin-ﬁlm printed gate electrode was replaced by a sterling silver immersed elec-
trode (as shown in the ﬁgure 2.3a schematic) to negate the eﬀect of oxidation at
the gate. Furthermore, a laser cut perspex well was attached to the sensor to con-
strain the PBS droplet on the surface of the sensor. The new print conﬁguration
(excluding the gate electrode and perspex well) is shown in ﬁgure 4.4.
Figure 4.4: Third OECT design iteration showing the removal of the thin-ﬁlm gate
electrode.
The OECT output characteristics for the third iteration are shown in ﬁgures C.7
and C.8. Here, to ensure that the semiconductor was not broken down due to
current spikes at the end of each sweep, the drain voltage sweep was changed
to include a backward sweep following the peak value of the forward sweep, as
shown in ﬁgure C.6. Additionally, the example output sweep shown here indicates
a positive gate sweep, which should show decreasing values for the drain current
in the output characteristics. In contrast, the output characteristics indicate an
increasing drain current for increasing gate voltages. Although ﬁgure C.7 does not
show conclusive information, ﬁgure C.8 shows the increasing trend in drain current
linked to an increasing gate current. Here, the drain current clearly followed
the gate current, with the gate current contributing towards the measured drain
current.
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Iteration 4: Addition of 5 µL Drop of PEDOT:PSS Semiconductor and
Widening of Channel
In the third iteration, the domination of the gate current was attributed to the
high transverse conductance and thin layer thickness of the PEDOT:PSS, allowing
current to ﬂow, with little resistance, between the immersed gate and the chan-
nel. Therefore, in the fourth and ﬁnal design iteration, two changes were made
to ensure the gate electrode aﬀected the doping level of the PEDOT:PSS only,
and did not contribute to the measured drain current. The ﬁrst change was to
dramatically increase the layer thickness of the PEDOT:PSS layer to ensure no
current ﬂow between the gate and the channel in a transverse direction, and to
increase the capacity of the PEDOT:PSS layer for ion transfer between itself and
the electrolyte. The second change was to increase the channel width, allowing the
doping level of the semiconductor to have a larger eﬀect on the channel current,
by increasing the length of the current path through the PEDOT:PSS.
The PEDOT:PSS layer thickness was increased by replacing the 10 inkjet printed
layers with a single 5 µL drop of PEDOT:PSS ink, dispersed by a pipette. The
channel width was increased from 100 µm to 200 µm on the GIMP design. The
ﬁnal print conﬁguration (excluding the gate electrode and PEDOT:PSS layer) is
shown in ﬁgure 4.5. The fabrication process of this iteration is detailed in section
4.4.1.
Figure 4.5: Fourth and ﬁnal OECT design iteration showing the increased channel
width and removal of the PEDOT:PSS layers.
The output characteristics of the fourth OECT design iteration are shown in ﬁg-
ures C.10 and C.11. It can be seen by these ﬁgures that this iteration exhibited
output characteristics indicative of an OECT. Here, an increasing gate voltage
caused a corresponding increase in the amount of cations being injected into the
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semiconductor, thus decreasing the doping level and the resulting channel current
in the semiconductor. This resulted in an overall decrease in drain current corre-
sponding to the increase in gate voltage.
A detailed characterisation of the working organic electrochemical transistors de-
veloped as described, showing the output and transfer characteristics, is given in
section 5.3.
4.3 Measurement System Design
The measurement system has two main objectives, the ﬁrst being to fully charac-
terise the sensor, and the second being to perform the ﬁnal sensor measurements.
According to ﬁgure 3.2, the measurement system is made up of four components:
supply signal to the sensor, output signal conditioning, output signal measure-
ment and recording, and signal processing and display. The requirements of the
measurement system are listed in section 3.2.3.
4.3.1 Measurement System Selection and Design
The sensor design, described in section 4.2, indicated that an organic electrochem-
ical transistor with the p-doped organic semiconductor, PEDOT:PSS, was chosen
and designed as the sensor. OECTs are three channel devices that consist of a
source, drain and gate electrode, similar to the well-known MOSFET transistor.
Since the majority carriers in p-doped semiconductors are holes, the OECT can
be schematically represented by a PMOS transistor. The connection diagram for
interfacing the measurement system with the OECT, represented by a PMOS
transistor, is shown in ﬁgure 4.6.
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Figure 4.6: Diagram showing voltage supply and measurement points for the
OECT, represented by an PMOS transistor.
Here, the source electrode is connected to ground, whilst the input signals are sup-
plied at the gate (VGG) and the drain (VDD) electrodes respectively. Four voltage
signals require measuring in order to fully characterise the transistor and deter-
mine current ﬂow through the device. These are the two supply voltages: Vgg and
Vdd, and the voltages at the gate and drain terminals: (Vgs) and (Vds). By inserting
resistors of known magnitude at the drain and gate terminals, the respective drain
current (Id) and gate leakage current (Ig) can be determined by Ohm's Law, since
the voltages at each end of the resistor are known.
Instruments considered for the supply, measurement, recording and display of sig-
nals included microcontrollers, source meters, and data acquisition devices. The
advantage of a microcontroller is its small and compact size, however, its use
would require many peripheral components. Source-meters, such as the Keithley
SourceMeter series, are often used for device characterisation and sensor measure-
ments in literature [44]. These, however, are highly costly and were therefore
not considered. Data acquisition devices (DAQs), especially National Instruments
DAQs controlled by LabVIEW software, were used for device characterisation and
sensor measurements in some literature, showing good performance [30].
The National Instruments Compact Data Acquisition (NI-cDAQ) system was found
to be a convenient platform for the integration of many of the required hardware
components, allowing a combination of hardware to be controlled by a single virtual
user interface based on the LabVIEW software. This device, with a 16-channel
diﬀerential input analogue-to-digital converter (ADC) module, as well as a 16-
channel digital-to-analogue converter (DAC) module was chosen as the integrated
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supply and measurement device. Furthermore, the device was coupled to the
LabVIEW measurement software for control, signal conditioning, processing and
display purposes, thus satisfying all requirements stated in section 3.2.3. The NI-
cDAQ, showing the NI 9205 ADC module and the NI 9264 DAC module, as well
as the DAQ connection diagram, are shown in ﬁgure 4.7. The DAQ was connected
(a) Connection diagram of the NI cDAQ.
(b) Photo of the NI cDAQ showing the
9205 ADCmodule and the 9264 DACmod-
ule.
Figure 4.7: Connection diagram and photo of the NI cDAQ.
directly to the OECT via a PCB mounted in a 3D printed chassis. The PCB,
containing the drain and gate resistors, was connected to the supply and measure-
ment DAQ channels via shielded wires on the one end, and was connected to the
OECT electrode contacts via spring-loaded contact pins on the other end. The
immersed silver gate electrode was held into the PBS electrolyte via a suspended
crocodile clip. This set-up is shown in ﬁgure 4.8.
4.3.2 LabView Control and Measurement Programs
The LabVIEW software was used to control the output signals of the DAQ and
to record the input signals read at the outputs of the transistor. Three diﬀerent
programs were developed in LabVIEW. The ﬁrst program was used to send con-
stant DC voltages to both the drain and gate electrodes. The second program was
designed to supply a constant value at one electrode, and sweep the voltage at
the second electrode. This was used for the transfer sweep in order to develop the
transfer curves. The ﬁnal program was designed to sweep both the drain and the
gate voltages sent to the OECT in order to determine the output characteristics of
the transistor. The block diagrams corresponding to the three separate LabVIEW
programs, as well as the designed virtual interface (VI), are shown in appendix E.
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Figure 4.8: Sensor connection set-up.
4.4 Integrated Sensor Fabrication for Final
Testing
The following section describes the process of fabricating a fully functional OECT,
followed by the process of antibody immobilisation onto the OECT surface. This
was the process followed for the fabrication and activation of the ﬁnal sensors.
4.4.1 OECT Fabrication
The 6 step OECT fabrication process is listed below:
1. Print a batch of electrodes onto the Mitsubishi paper using the inkjet printer.
2. Spin coat the entire batch of transistors with S1818 photoresist. The spin
coating process is described as:
(a) spin the sample at 600 rpm whilst rapidly dripping 1 mL of photoresist
at the center of the sample.
(b) after 30 seconds, gently ramp the speed to 2000 rpm over 5 seconds.
(c) leave the sample to spin for an additional 5 to 10 seconds before stop-
ping.
Figure 4.9 shows the electrodes before (i) and after (ii) spin coating, whilst
the third image (iii) shows the result of incorrect spin coating, with the
photoresist clearly covering the electrodes.
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Figure 4.9: Optical microscope images of the OECT electrodes: i) before spincoat-
ing, ii) after spin coating, iii) incorrect spin coating.
3. Bake the spin coated electrodes at 100 degrees Celsius for one hour.
4. Add 5 µL drops of PEDOT:PSS onto the electrode area, ensuring the channel
is properly covered, as shown in ﬁgure 4.10a.
5. After adding the PEDOT:PSS drops, bake the transistors (shown in ﬁgure
4.10a) at 100 degrees Celsius for 2 hours, resulting in a thin ﬁlm of PE-
DOT:PSS covering the electrodes, as shown by ﬁgure 4.10b.
6. Add the clean laser cut perspex wells to each transistor, taking care not to
contaminate the PEDOT:PSS layer.
(a) Addition of the 5 µL drop of PE-
DOT:PSS to a printed and spin coated
batch of OECTs.
(b) Optical microscope image of the PE-
DOT:PSS drop on the sensor, after bak-
ing.
Figure 4.10: 5 µL drop of PEDOT:PSS before and after baking.
After this fabrication process, the OECT is ready for capture antibody immobili-
sation.
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 4. DESIGN FINALISATION AND MANUFACTURE 58
4.4.2 Antibody Immobilisation onto OECT Sensor
The antibody immobilisation method consists of four main steps and is conducted
over two days. A more detailed description of the immobilisation method, includ-
ing the relevant reagent preparations, is given in appendix F.1. The four main
steps are:
1. Immobilise streptavidin to the surface of the PEDOT:PSS layer.
2. Biotinylate the capture antibodies.
3. Immobilise the biotinylated capture antibodies to the sensor.
4. Add BSA to block all unbound binding sites.
After immobilisation, the OECT immunosensor is fully functional and ready to
test.
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System Validation
5.1 Antibody Pairing Tests
The purpose of the antibody pairing tests were to determine the optimal capture-
detection antibody pair, from the ordered antibodies. The performance of an
antibody pair reﬂects the eﬀectiveness of the antibody-antigen binding process,
which has a major eﬀect on the sensitivity of an immunosensor. Put simply, the
more antigens (proteins) that bind to the capture antibodies, and the more detec-
tion antibodies that subsequently bind to those antigens (proteins), the stronger
the signal and the higher the sensitivity of the biorecognition process.
5.1.1 Test Description
Two diﬀerent immunoassays were used for the respective antibody pairings - a meso
scale discovery (MSD) electrochemiluminescence (ECL) assay, and an enzyme-
linked immunosorbent assay (ELISA). These immunoassays are the current lab-
oratory standard for CRP and PCT detection and quantiﬁcation and are brieﬂy
described in section 2.2.4. The CRP pairing was done on MSD and the PCT pair-
ing was done on ELISA, due to the quantity of ordered PCT antibodies being too
small to justify an MSD test.
The methodology followed for the antibody pairing tests is comprehensively docu-
mented in appendix B, while the results are given in the following section, section
5.1.2.
5.1.2 Antibody Pairing Results
The results of the pairing tests for CRP and PCT are shown in ﬁgure 5.1.
59
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 5. SYSTEM VALIDATION 60
(a) Results from the MSD test for CRP antibody pair-
ing
(b) Results from the ELISA test for PCT antibody
pairing
Figure 5.1: Antibody pairing test results for CRP and PCT respectively
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The plots shown in ﬁgure 5.1 were constructed from the raw data acquired from the
MSD and ELISA tests respectively. Both the MSD and ELISA assays detect the
the change in signal strength for diﬀerent antigen concentrations (in an analyte)
with respect to a blank control (containing no antigens). As stated in the method-
ology, sequential concentrations of the analyte, being CRP and PCT proteins in
phosphate buﬀered saline (PBS), were added to every second well of the assay.
Thus, two of the same analyte concentration were tested side-by-side for averaging
purposes. The plots, therefore, show two slightly diﬀerent signal strengths for the
same concentration, with the dotted line joining the average signal strength for
each sequential concentration.
Three diﬀerent antibody pairs were tested for CRP according to the MSD method-
ology described in appendix B.2: Capture - Detection 1, Capture - Detection 2, and
Capture - Detection 3. From the results shown in ﬁgure 5.1a, there are distinct dif-
ferences in performance shown for the three respective pairings. The performance
of a particular antibody pair is shown by the gradient of the averaged data points,
that is, the degree to which the change in antigen concentration (independent
variable) causes a corresponding change in signal strength (dependent variable).
According to this, the best performing pair of CRP antibodies was the "Capture-
Detection 1" pair, showing an overall higher signal strength as well as the steepest
gradient over the given concentration range.
Similarly, two diﬀerent antibody pairs for PCT were tested according to the ELISA
methodology described in appendix B.1: Capture 1 - Detection and Capture 2 -
Detection. The results of this test are plotted in ﬁgure 5.1b. Here, the "Capture
1 - Detection" pair showed the highest sensitivity, with a higher overall signal
strength and a steeper gradient over the concentration range.
From these results, the antibody pairs selected for the ﬁnal system design and
testing were: "Capture - Detection 1" for CRP, and "Capture 1 - Detection" for
PCT.
5.2 Measurement System Validation
The measurement system was validated in three diﬀerent ways. First, the outputs
of the DAC module were veriﬁed with an oscilloscope to determine the accuracy of
the controlled output voltages. The DAC module performed satisfactorily in these
tests. Secondly, the inputs of the ADC module were tested by inputting known
voltages, and comparing the measured signal to the simultaneously measured oscil-
loscope reading. Again, the ADC module performed satisfactorily. The third test
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conducted to validate the measurement system was to test the ability of the system
to characterise an oﬀ-the-shelf NMOS transistor. Here, the NMOS transistor was
connected to the measurement set-up and the three diﬀerent LabVIEW programs
were used to fully characterise the transistor. The results from testing the output
sweep program are shown in ﬁgure 5.2. The output curves correspond with those
shown in the datasheet of this particular NMOS, therefore validating the output
sweep measurement program. In the same way, the transfer sweep program as well
as the constant DC output program, were validated. The measurement system,
therefore, showed good performance and was considered ready to perform OECT
characterisation and ﬁnal sensor tests.
Figure 5.2: Output curves for the NMOS transistor for validation of the output
sweep program developed in LabVIEW.
5.3 OECT Characterisation and Validation
The fourth iteration described in the OECT design process (section 4.2), led to
the ﬁrst working OECT. That is, the ﬁrst OECT exhibiting output characteristics
required for classiﬁcation as an organic electrochemical transistor. Furthermore,
in order to use the OECTs as sensors, it is ﬁrst required that their output and
transfer characteristics be known, for the OECT operating point (or biasing point)
to be determined.
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The OECTs were characterised using the NI cDAQ and corresponding measure-
ment set-up, controlled by the relevant the LabVIEW programs, described in sec-
tion 4.3. There were slight deviations in the performance and characteristics of
diﬀerent OECTs due to inconsistencies inherent to the manual fabrication process.
The output and transfer characteristics of a selected transistor are described in
this section. The characteristics of three other OECTs are given in appendix D.
5.3.1 Output Characteristics
The output characteristics of the OECT were determined by conducting an output
voltage sweep and measuring the response of the transistor to each incremental
gate voltage, using the measurement system described in section 4.3. The output
characteristics are shown in ﬁgure 5.3.
Figure 5.3: OECT output characteristics for a gate voltage varying from 0.75 to
0.25 V.
The output characteristics of the OECT resemble those found in literature [44; 51],
such as those shown in ﬁgure 2.5 [46]. These results show an increasing gate volt-
age causing a corresponding decrease in drain current, as a result of a reduction
in the ion penetration (de-doping) of the PEDOT:PSS. They also indicate two
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speciﬁc regions - a non-saturation and a saturation region. In the non-saturation
region, the drain current is dependent on both the source-drain voltage and the
gate voltage. In the saturation region, the drain current in dependent on the gate
voltage alone, and is independent of the source-drain voltage. This is particularly
useful in ampliﬁcation and sensing applications, where the OECT is typically bi-
ased in the saturation region. Furthermore, ﬁgure 5.3 shows a diﬀerence in the
measured value between the forward and backward sweeps, known as hysteresis
error. Hysteresis error indicates that the output of the system at a speciﬁc point is
dependent on the previous state, which aﬀects the repeatability of a device. This
dependency is brought about by the capacitive eﬀects of residual charge trapped
in the semiconductor, as well as the low ion mobility limiting the response time of
the OECT.
5.3.2 Transfer Characteristics
The transfer characteristics of the OECTs were determined by biasing the OECT
at a speciﬁc drain voltage, and sweeping the gate voltage. The transfer curve along
with the corresponding gate leakage current are plotted in ﬁgure 5.4.
Figure 5.4: OECT transfer characteristics for a drain voltage of 0.34 V.
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 5. SYSTEM VALIDATION 65
The transfer characteristics are in agreement with those found in literature, such as
the transfer curve shown in ﬁgure 2.6. The transfer curve is useful in determining
both the turn-on voltage of the OECT and the point at which the peak transcon-
ductance occurs. Transconductance describes the extent to which a change in gate
voltage causes a corresponding change in drain current. It is, therefore, the main
transistor parameter that governs signal ampliﬁcation, and thus aﬀects the sensi-
tivity of OECT-based sensor. The transconductance is described by the gradient
of the transfer curve, with the peak transconductance occurring at the inﬂection
point (or point of steepest gradient) of the transfer curve. Figure 5.5 shows the
transconductance plotted for the transfer curve shown in ﬁgure 5.4. From this, the
peak transconductance occurs at Vsg = −0.5 V.
Figure 5.5: Transfer characteristics plotted with corresponding DC transconduc-
tance (δId/δVg).
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Results and Discussion
The following chapter ﬁrst describes the tests that were conducted to evaluate the
performance of the immunosensor. It then presents the results of each test, both
for CRP and PCT, and ﬁnally discusses the results from the tests in order to draw
a conclusion on the sensor performance.
6.1 Test Description and Methodology
In order to test the performance of the OECT-based immunosensors, for both CRP
and PCT, three diﬀerent tests were conducted, using the measurement system and
LabVIEW programs described in section 4.3. Each test was designed with the lit-
erature and the objectives in mind. Literature showed that the sensing mechanism
relied on the change in eﬀective gate voltage due to the binding of the biomarkers
to cause a change in the drain current, whilst the objectives imposed a time limit
on the tests.
The sensors for these tests were fabricated according to the method described
in section 4.4, while the AuNP-labelled detection antibody solution and the PBS-
buﬀered recombinant protein dilutions required for each test were prepared ac-
cording to the methodology described in appendix F.2.
6.1.1 Test 1
The goal of the ﬁrst test on the OECT immunosensors was to qualitatively deter-
mine the eﬀect of the serial addition of recombinant protein dilutions, buﬀered in
PBS, on the transfer characteristics of a transistor. Analogous to cyclic voltamme-
try, this was done by biasing the OECT at a drain voltage of VDD = −0.4 V, whilst
sweeping the gate voltage back and forth between VGG = 1.2 V and VGG = −0.2 V,
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and adding sequential protein dilutions at the start of each sweep (i.e. where
VGG = 1.2 V). In order to determine the eﬀect of the addition of ions to the sys-
tem when adding PBS (in which the proteins were buﬀered), this test was ﬁrst
done by adding PBS only, to establish a baseline. The test was then repeated three
more times with the sequential protein dilutions. The pair of each forward and
backward sweep took about 100 seconds, and the elapsed time for each test was
about 15 minutes. Furthermore, it should be noted that this test was done with
the recombinant proteins only, and the AuNP-labelled detection antibodies were
not added, due to the nature of the test requiring sequential addition of diﬀering
protein dilutions. The results of this test, for PBS only, CRP and PCT, are shown
in section 6.2.1, where the drain current is plotted against the source-gate voltage
for each test.
6.1.2 Test 2
The second test was designed with the goal of establishing a calibration curve for
the immunosensors (like that shown in ﬁgure 2.9), in which a certain concentration
corresponds to a speciﬁc change in drain current. In this test, the OECT was
initially biased at VGG = 0.4 V and VDD = −0.4 V, and the OECT's response to a
gate voltage step was measured by stepping the gate voltage from 0.4 V to 0.8 V.
The gate voltage was stepped one minute after adding: PBS, a single dilution of
recombinant proteins, and the AuNP-labelled detection antibodies. This was done
for six diﬀerent recombinant protein dilutions in an attempt to quantify the eﬀect
of protein binding, and subsequent AuNP-labelled detection antibody binding,
on the response of the sensor. Figure 6.4 shows the results of stepping the gate
voltage after adding PBS, a CRP recombinant protein dilution at a concentration
of 20 µg/mL, and the labelled detection antibodies. The calibration curves were
subsequently determined by plotting the normalised change in drain current in
response to the corresponding gate voltage step, for each diﬀerent protein dilution.
The calibration curves are shown for CRP in ﬁgures 6.5 and 6.6, and PCT in ﬁgures
6.7 and 6.8.
6.1.3 Test 3
The third test, in a similar way to the ﬁrst test, was concerned with determining the
eﬀect of protein binding on the transfer characteristics of the sensor. However, in
this case, the transfer characteristics were determined before the addition of a pro-
tein dilution and after the addition of both a protein dilution and AuNP-labelled
detection antibodies. This was done by ﬁrst performing a transfer sweep with
PBS, thereafter adding a dilution of recombinant proteins, waiting ﬁve minutes
before adding the AuNP-labelled detection antibody reagent, waiting another ﬁve
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minutes, and ﬁnally conducting another transfer sweep. In this case, the sweeps
were conducted by biasing the sensor at VDD = −0.4 V and sweeping the gate
voltage from VGG = 1 V to VGG = −0.2 V, in the forward direction only. These
tests were done with six diﬀerent recombinant protein concentrations, and the re-
sults before and after the addition of a recombinant CRP dilution, at a particular
concentration, are plotted in ﬁgure 6.9. To establish a calibration curve from each
set of results, the normalised change in drain current (at a speciﬁc source-gate
voltage) before and after having added the particular recombinant protein dilu-
tion and AuNP-labelled detection antibodies, were plotted. These are shown for
CRP and PCT in ﬁgures 6.10 and 6.11 respectively.
6.2 Test Results
6.2.1 Test 1
Figure 6.1: Eﬀect of cumulative addition of PBS on the sensor transfer character-
istics.
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Figure 6.2: Eﬀect of sequential addition of CRP on sensor transfer characteristics.
Figure 6.3: Eﬀect of sequential addition of PCT on sensor transfer characteristics.
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6.2.2 Test 2
Figure 6.4: Example of the response of the sensor after adding PBS, CRP protein
at a concentration of 20 µg/mL, and the the AuNP-labelled detection antibody
reagent.
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Figure 6.5: Calibration curve for the addition of varying CRP protein concentra-
tions: 0.3125 µg/mL; 0.625 µg/mL; 1.25 µg/mL; 2.5 µg/mL; 10 µg/mL and 20
µg/mL.
Figure 6.6: Calibration curve after the addition of AuNP-labelled detection anti-
bodies for the same varying CRP protein concentrations shown in ﬁgure 6.5.
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Figure 6.7: Calibration curve for the addition of varying PCT protein concentra-
tions: 0.015625 µg/mL; 0.03125 µg/mL; 0.0625 µg/mL; 0.0125 µg/mL; 0.5 µg/mL;
1 µg/mL.
Figure 6.8: Calibration curve after the addition of AuNP-labelled detection anti-
bodies for the same varying PCT protein concentrations shown in ﬁgure 6.7.
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6.2.3 Test 3
Figure 6.9: Example of the sensor transfer curve before and after addition of CRP
protein at a concentration of 0.3125 µg/mL and the the AuNP-labelled detection
antibody reagent.
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Figure 6.10: Sensor calibration curve for the six CRP concentrations: 0.3125
µg/mL; 0.625 µg/mL; 1.25 µg/mL; 2.5 µg/mL; 10 µg/mL and 20 µg/mL
Figure 6.11: Sensor calibration curve for the six PCT concentrations: 0.015625
µg/mL; 0.03125 µg/mL; 0.0625 µg/mL; 0.0125 µg/mL; 0.5 µg/mL; 1 µg/mL.
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6.3 Discussion of Results
6.3.1 Test 1
The ﬁrst plot shown for test 1, in ﬁgure 6.1, demonstrates the change in transfer
characteristics of the OECT sensor, immersed in PBS, to the addition of more
PBS buﬀer at the start of each gate voltage sweep. According to literature, the
addition of ions to the operational electrolytic solution by increasing the volume of
electrolyte should result in a change in the "turn on" voltage of the transistor [26].
Here, it was indeed observed that the addition of ions to the system shifted the
"turn on" voltage of the transistor in the positive Vsg direction, without aﬀecting
the peak value of the sweep.
Figure 6.2 shows the eﬀect of the sequential addition of varying CRP protein
concentrations on the transfer characteristics of the sensor. Here, the "turn on"
voltage of the sensor clearly shifted with increasing ion levels, due to the addi-
tion of PBS buﬀer containing the protein concentrations. In contrast to ﬁgure
6.1, however, the drain current decreased (shifted down) with increasing protein
concentrations, indicating a response to the addition of the CRP proteins.
In this test, the sequential addition of varying PCT concentrations had no ef-
fect on the transfer characteristics of the sensor, as shown in ﬁgure 6.3. Here,
there is an evident shift in the "turn on" voltage of the sensor due to increasing
ion levels with the addition of PBS buﬀer; however, unlike the CRP sensors, there
is no evident downward shift in the drain current. Additionally, the transfer curves
are less well deﬁned and show more ﬂuctuation than the curves shown in the CRP
tests.
6.3.2 Test 2
The plot shown in ﬁgure 6.4 demonstrates the drain current response to a gate
voltage step: 1. after adding PBS, 2. after adding CRP protein buﬀered in PBS
at a concentration of 20 µg/mL, and 3. after adding AuNP-labelled detection
antibody reagent buﬀered in PBS. This plot shows an observable change in drain
current response for each respective step, indicating increased sensitivity of the
drain current to changes in the gate voltage after the addition of CRP protein
and the subsequent addition of AuNP-labelled detection antibodies. With the
goal of drawing sensor calibration curves, the same test was conducted on diﬀer-
ent CRP sensors for six diﬀerent concentrations of CRP protein, between 20 and
0.3125 µg/mL. These tests showed similar responses to the example shown in ﬁgure
6.4. From these, the normalised drain current response for each concentration was
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determined by dividing the size of the drain current step (Id-Id0) by the starting
current (Id0). The two corresponding calibration curves are shown in ﬁgures 6.5
and 6.6.
The calibration curve, for the addition of CRP proteins only, shows a clear in-
creasing trend for increasing CRP concentrations. This indicates that the sensor
was sensitive to varying CRP protein concentrations, detecting CRP protein at a
minimum concentration of 0.3125 µg/mL. The calibration curve showing the eﬀect
of the addition of AuNP-labelled detection antibodies, also indicates an increasing
trend for increasing CRP concentrations. The AuNP-conjugated detection anti-
bodies increased the size of the overall change in drain current slightly, in eﬀect
amplifying the detected signal, which is in line with the literature [29; 50].
The PCT sensors were tested by the same methodology described above and shown
in ﬁgure 6.4. Here, neither of the two calibration curves, shown in ﬁgures 6.7 and
6.8, show any discernible trend. In the same way as described in test 1, the PCT
sensors displayed high variability and no response to the PCT protein.
6.3.3 Test 3
The third and ﬁnal test demonstrated the change in the transfer characteristics
of the sensors, after a ﬁve minute incubation period, immersed in the recombi-
nant protein reagent, and a subsequent ﬁve minute incubation period immersed
in the AuNP-labelled detection antibody reagent. Here, the downward shift in
the transfer curve at a speciﬁc source-gate voltage, before and after the addition
of biomolecules, was determined, as shown in ﬁgure 6.9. This, again, was carried
out for six varying concentrations of recombinant CRP protein. The normalised
downward shift (or diﬀerence) in drain current, corresponding to each diﬀerent
concentration, is plotted on the calibration curve shown in ﬁgure 6.10.
The ﬁrst observation from the calibration curve shown for CRP, is the increas-
ing trend in the normalised diﬀerence in drain current for increasing CRP con-
centrations, indicating that the sensor was indeed able to detect the diﬀerent
concentrations of CRP protein. A second, and important, observation from the
calibration curve, is the resemblance of this calibration curve to the second cali-
bration curve from test 2, shown in ﬁgure 6.6. In both instances, CRP protein as
well as AuNP-labelled detection antibody reagent were added to the sensor, with
the sensor responding in an identical manner.
The calibration curve shown for the PCT sensors was developed in the same way
as for the CRP tests described above, and is shown in ﬁgure 6.11. By discounting
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the second lowest PCT concentration, there is clearly no increasing trend shown
in the diﬀerence in drain current.
6.3.4 General Discussion
The three tests detailed above demonstrate the performance of the initial prototype
sensors in the detection of CRP and PCT proteins. The CRP sensors successfully
detected sequential concentrations of CRP protein in PBS buﬀer down to a limit
of 0.3125 µg/mL. The addition of the AuNP-labelled detection antibodies in tests
2 and 3 increased the sensitivity of the sensors slightly, and the calibration curves
are shown to be identical. This observation, therefore, validates the sensitivity of
the CRP sensor to the addition of varying CRP concentrations between 0.3125
and 20 µg/mL. It should be noted that due to the pioneering nature of this work,
the value of the results was to obtain semi-quantitative responses to diﬀerent con-
centrations of CRP, and in this phase of their development, the CRP sensors were
not statistically validated.
The PCT sensors on the other hand did not show any response to varying con-
centrations of PCT protein in PBS buﬀer. The main observation in this regard
was that the actual OECTs showed hindered performance after the PCT capture
antibody immobilisation. Possible causes for this hindered functionality may be
the longer storage time of the PCT sensors in the capture reagent prior to testing,
causing the PEDOT:PSS semiconductor layer to lose functionality by dissolving
into solution. Additional causes for the lack of sensor performance may have been
the denaturing of the capture antibodies prior to testing, or human pipetting error
in the capture antibody immobilisation procedure. The PCT sensors could not be
re-tested due to an insuﬃcient amount of capture antibodies. Although only very
minute quantities of antibody are required per sensor, the antibody reagents are
prepared in a single batch, and denature over time, thus limiting the amount of
tests that can be carried out.
Furthermore, it is important to note that all tests were carried out using PBS
buﬀer for the dual purpose of analyte and functional electrolyte. The reason for
this being that the initial testing and optimisation of immunosensors is simpler
and more practical in PBS since both the initial ion and biomarker concentrations
are known at all times and can be easily adjusted. As the end goal of the sensor
is to measure serum or saliva concentrations of CRP and PCT, in vitro, to assist
in the screening for infectious diseases, the working electrolyte and analyte will
have to be replaced by one of these biological ﬂuids in the next phase of work.
The use of biological ﬂuids will have a negative eﬀect on the sensor performance.
Although the ion concentrations of PBS match those of the human body, biologi-
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cal ﬂuids (such as serum) contain many other biological substances (not only the
target biomarker) that can increase the noise of a reading, thus interfering with
the correct detection of the target biomarker.
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Chapter 7
Closing Summary, Conclusions and
Recommendations
For ease of reference, the following chapter is divided into three sections. The ﬁrst
section oﬀers a closing summary of the work ﬂow; the second section concludes on
the reported project and the third section oﬀers recommendations for future work
in order to further develop the device.
7.1 Closing Summary
One of the main factors contributing to the imminent threat of antimicrobial re-
sistance is the misappropriation of antibiotics, due to the lack of clinically diﬀer-
entiable features distinguishing bacterial infection from viral infection. Some clin-
icians have access to the testing of a broad array of quantiﬁable markers, known as
biomarkers, that can aid in screening for infectious diseases; however, most exist-
ing biomarker tests require well-equipped laboratory set-ups, are highly costly and
are time-consuming. Furthermore, in resource-poor settings, lacking well-equipped
laboratories, clinicians do not have access to these tests. The costliness, time re-
quired and infrastructure needed to perform these biomarker tests often leads to
clinicians making decisions based on clinical symptoms alone.
With the above in mind, the aim of the reported project was to develop a rapid
biomarker test to aid in the screening of infectious diseases. The main objectives
of the project were listed in section 1.3.
In the literature, C-reactive protein (CRP) and procalcitonin (PCT) have been
shown to hold much promise as biomarkers for infectious diseases. Their combi-
nation has been recommended for the diﬀerentiation between bacterial and viral
79
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infections, since CRP is sensitive to both viral and bacterial infections and PCT
is sensitive to bacterial infections. These advantages, amongst others described in
section 2.1, led to these biomarkers being chosen as the targets for the rapid test.
In addition to the selection of appropriate target biomarkers, it was also required
that a suitable sensing method be selected. To that end, an organic electrochem-
ical transistor (OECT) based immunosensor, as a subclass of organic thin-ﬁlm
transistors (OTFTs), was chosen as the sensing platform, due to their low cost,
simple fabrication, high sensitivity and good biocompatibility.
Three main subsystems were identiﬁed for the development of the rapid biomarker
test. These are: (1) the biorecognition elements; (2) the sensor; and (3) the mea-
surement system.
For the biorecognition element subsystem, a sandwich-type immunosensor conﬁg-
uration was chosen, consisting of a capture antibody and a nanoparticle-labelled
detection antibody. Diﬀerent antibodies were ordered for both CRP and PCT,
and gold nanoparticles (AuNPs) were chosen as the detection antibody label due
to their reported signal ampliﬁcation ability. The performance of the diﬀerent
capture-detection antibody pairs were tested on ELISA and MSD respectively,
with the results indicating that the "capture - detection 1" antibody pair for CRP,
and the "capture 1 - detection" antibody pair for PCT, yielded the highest signal
strength and thus sensitivity to the binding of the target biomarkers.
For the sensor platform, the OECTs were designed to be fabricated with the low
cost inkjet printing method, using a combination of silver nanoparticle ink for
the electrodes and PEDOT:PSS organic semiconductor ink for the semiconductor
layer. After many design iterations (the four most signiﬁcant iterations reported
on in section 2.4.3), and over 300 diﬀerent tests, a working organic electrochemi-
cal transistor prototype was developed according to the methodology described in
section 4.4.1, and characterised as shown in section 5.3.
The measurement system was comprised of the National Instruments cDAQ data
acquisition system coupled to LabVIEW control software. This system was used
to perform all required OECT characterisation tests as well as ﬁnal sensor tests.
The measurement system was veriﬁed by successfully characterising an oﬀ-the-
shelf NMOS transistor.
For the ﬁnal tests, the OECTs were fabricated and coupled to the capture an-
tibodies according to the biotin-streptavidin immobilisation method, described in
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section 4.4, to produce the immunosensors. Three primary tests were conducted
on the immunosensors to assess their performance, as described in section 6.1.
The results of these tests, shown in section 6.2, indicated that the CRP sensors
detected sequential concentrations of recombinant CRP protein, between 0.3125
and 20 µg/mL. Furthermore, the addition of AuNP-labelled detection antibodies
indicated an ampliﬁcation in measured signal strength, which is in accordance with
literature. In contrast, the PCT sensors exhibited no measurable change in signal
in response to the addition of the PCT protein dilutions.
7.2 Conclusions
One of the main ﬁndings was that the project successfully demonstrated functional
paper-based, inkjet-printed, organic electrochemical transistors (OECTs). It was
found that the main success factors for a working OECT were: increased layer
thickness of the organic semiconductor, resistance of the gate electrode to oxida-
tion and the paper substrate's resistance to liquid seepage. This is an important
ﬁnding since it enables the simple and low-cost production of disposable organic
electrochemical transistors that can be used not only for sensing, but a variety of
organic printed electronics, provided an electrolytic solution (like PBS) is used.
Furthermore, from the literature the clinically relevant CRP cut-oﬀ value for viral
infection is between 10 and 20 µg/mL, while for bacterial infection it is greater
than 20 µg/mL. For PCT, the clinically relevant cut-oﬀ value for bacterial infection
is 0.25 ng/mL. Although, at this phase of the development, the CRP sensors were
not statistically validated, the results indicate that the sensors did indeed respond
to changes in concentration within the clinically relevant range. The PCT sensors,
on the other hand, failed to respond to changes in PCT concentration due to the
deterioration of the sensors post immobilisation.
The CRP sensors, therefore, demonstrated an easily manufacturable and low cost
ﬁrst prototype, whilst the PCT sensors require further work. Apart from the faulty
PCT sensors, other limitations of the device include that the tests were solely con-
ducted in PBS buﬀer and not in biological ﬂuids, the fabrication of the sensors was
tedious and not fully automated (i.e. the addition of the PEDOT:PSS layer and
the antibodies was manual), and the sensors' performance deteriorated when ex-
posed to aqueous conditions for longer time periods (as described in section 6.3.4).
In conclusion, the following objectives of the project (as stated in section 1.3)
were achieved: (1) the CRP and PCT proteins were chosen as ideal biomarkers
for the screening of infectious diseases; (2) an OECT-based immunosensor was
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identiﬁed as the ideal biosensing technique for the low-cost and rapid detection
of CRP; (3) a prototype sensor, based on OECT immunosensor technology, was
designed and fabricated; (4) a measurement system for the sensor was designed
and validated; (5) the main components of the prototype sensor were successfully
validated; the performance of the prototype sensors were tested, with the CRP
sensors showing good sensitivity to CRP protein concentrations between 0.3125
and 20 µg/mL. The PCT sensors, on the other hand, showed no response to the
addition of PCT protein.
However, the CRP sensors, as is, require further reﬁnement before they can be
used as a ﬁrst screening method for infection, as do the PCT sensors. Recommen-
dations for future work are described in the following section.
7.3 Recommendations for Future Work
It is recommended that future work should ﬁrst focus on further development
of the PCT sensors to ensure they respond to varying concentrations of PCT.
This could be done by ensuring that the sensors are tested directly after antibody
immobilisation and are not stored for extended time periods in aqueous environ-
ments, by experimenting with other low cost substrates with better performance
in aqueous conditions (such as various polymers), or by making the PEDOT:PSS
semiconductor less soluble once deposited onto the substrate. Additionally, further
testing of the CRP sensors is required in order to develop repeatable calibration
curves for the sensors, in which speciﬁc CRP concentrations correlate to speciﬁc
changes in signal strength. The same should be done once working PCT sensors
are developed. Once both the CRP and PCT sensors function correctly, calibra-
tion curves should be generated in biological ﬂuid, such as serum or saliva, in order
to determine the performance of the sensors in vitro. These sensors should then
be statistically validated in biological media.
From a manufacture standpoint, the manufacture method requires increased au-
tomation, in which both the PEDOT:PSS semiconductor as well as the capture
antibodies are deposited in an automated process, such as inkjet printing. This in
turn will dramatically increase their repeatability and overall performance, their
manufacture time and their cost.
Finally, the current measurement system is unsuitable for many point-of-care
(POC) applications due to its high cost, large size and requirement for the Lab-
VIEW software on up-to-date PC hardware. Future work should, therefore, focus
on developing a portable device, able to run the respective tests in any setting.
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A.1 CRP Capture 1
Product name Anti-C Reactive Protein antibody
Description Rabbit polyclonal to C Reactive Protein
Host species Rabbit
Tested applications Suitable for: ELISA, WB, Immunoelectrophoresis, Immunodiffusion, IHC-P
Species reactivity Reacts with: Human
Immunogen Full length native protein (purified) (Human).
Positive control This antibody gave a positive result in IHC in the following FFPE tissue: Human normal liver.
Form Liquid
Storage instructions Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long
term.
Storage buffer Preservative: 0.02% Sodium Azide
Constituents: 0.14M Sodium chloride, 10mM PBS, pH 7.2
Purity Protein A purified
Purification notes Purity wad determined by SDS PAGE (blue stain), showing that the IgG constitute was greater
than 90% of total protein.
Clonality Polyclonal
Isotype IgG
Product datasheet
Anti-C Reactive Protein antibody ab31156
2 Abreviews 2 References 1 Image
Overview
Properties
Applications
Our Abpromise guarantee covers the use of ab31156 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application Abreviews Notes
ELISA Use at an assay dependent concentration.
1
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C-reactive/CRP Monoclonal Antibody                                            
CATALOG NO: 
 
ALTERNATIVE NAMES: 
 
AMOUNT: 
 
IMMUNOGEN: 
 
HOST/ISOTYPE: 
 
SPECIES REACTIVITY: 
 
PURIFICATION: 
 
FORM: 
 
FORMULATION:   
                  
STORAGE CONDITIONS: 
 
 
DESCRIPTION: 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPLICATION: 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
A1208-100          
 
CRP, PTX1, C-reactive protein 
 
100 µg 
 
Human CRP Protein 
 
Mouse IgG 
 
Human 
 
>95%, Protein G purified 
 
Liquid 
 
In NaCl with 15 mM NaN3 (pH 7.4) 
 
For long term storage store at -20°C in small aliquots to prevent 
freeze-thaw cycles. 
 
C-reactive protein (CRP) is an annular (ring-shaped), pentameric 
protein found in blood plasma, the levels of which rise in response 
to inflammation (i.e., C-reactive protein is an acute-phase protein 
of hepatic origin that increases following interleukin-6 secretion 
from macrophages and T cells). Its physiological role is to bind to 
lysophosphatidylcholine expressed on the surface of dead or dying 
cells (and some types of bacteria) in order to activate the 
complement system via the C1Q complex. CRP is synthesized by 
the liver in response to factors released by macrophages and fat 
cells (adipocytes).It is a member of the pentraxin family of proteins. 
It is not related to C-peptide (insulin) or protein C (blood 
coagulation). C-reactive protein was the first pattern recognition 
receptor (PRR) to be identified. 
 
ELISA, LEITA, LFIA 
 
Note: This information is only intended as a guide. The 
optimal dilutions must be determined by the user. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RELATED PRODUCTS: 
 
 Human CellExp™ C-reactive/CRP, human recombinant (Cat. No. 7242-100) 
 CRP, human recombinant (Cat. No. 4864-250, -1000) 
 
FOR RESEARCH USE ONLY!  Not to be used on humans. 
 
 
Fig1. Calibration curve for CRP in latex-enhanced turbidimetric 
immmmunoassay (LETIA): CRP proteins react with anti-CRP antibody 
precoated onto latex beads to form insoluble complex, resulting in turbidity 
increasing with was then detected by automatic biochemical analyzer. 
 
Fig2. Determination of the CRP concentration by serial dilution of clinical 
serum: The high value CRP serum was 2-fold serially diluted with physiological 
saline and measured on LETIA platform showed decline in CRP concentrations 
along with serial dilution of blood samples 
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A.2 CRP Detection
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Datasheet
 GeneTex, Inc : Toll Free 1-877-GeneTex (1-877-436-3839) Fax:1-949-309-2888 info@genetex.com
 GeneTex International Corporation : Tel:886-3-6208988 Fax:886-3-6208989 infoasia@genetex.com
Date : 2017/10/27
Catalog Number GTX14813                                     Package:100 μg         
Product Name Procalcitonin antibody [27A3]
Full Name calcitonin-related polypeptide alpha
Synonyms CALC1, CGRP, CGRP-I, CGRP1, CT, KC, MGC126648, CGRP I, CGRPI
Specificity Specific for N-terminal fragment
Background Procalcitonin (PCT) is a 116 amino acid residue peptide with molecular weight of about 13 kDa. The amino acid sequence of PCT
was firstly described by Moullec et al. in 1984. It belongs to a group of related proteins including calcitonin gene-related peptides I
and II, amylin, adrenomodulin and calcitonin (CAPA peptide family). PCT, like other peptides of CAPA family, appears from the
common precursor pre-procalcitonin consisting of 141 amino acids by removal of 25 a.a.r. from N-terminus. PCT is produced normally
in C-cells of the thyroid glands. It undergoes successive cleavages to form three molecules: N-terminal fragment (55 a.a.r.), calcitonin
(32 a.a.r.) and katacalcin (21 a.a.r.). It has been shown that the level of PCT in serum increases significantly during an infection of
bacterial origin (Assicot M, et al). Today PCT is considered to be one of the earliest and most specific markers of sepsis. However,
several studies revealed that elevated PCT level in human blood could be detected not only in case of sepsis and infection, but also in
cases of surgery, polytrauma, heat shock and cardiogenic shock (Meisner M. & Reinhart K). The importance of PCT measurements
in combination with cTnT or cTnI during heart transplantation to predict an early graft failure has been proved(Potapov EV., et al).
Host Mouse
Clonality Monoclonal
Clone Name 27A3
Isotype IgG2a
Immunogen Full length native protein, internal calcitonin fragment (purified) (Human)
Antigen Species Human
Species Reactivity Human
Applications ELISA, WB
Application Note This clone 27A3 can be used as the capture antibody and paired with clone 14A2 (GTX39509 Calcitonin antibody) for detection.
Cellular Localization Secreted
Conjugation Unconjugated
Form Supplied Liquid
Purification Protein A purified
Concentration Batch dependent (Please refer to the vial label for the specific concentration)
Storage Buffer Phosphate-buffered saline, pH 7.4, containing 0.1% sodium azide
Storage Instruction Keep as concentrated solution, aliquot and store at 4°C. Do not freeze.
Notes For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human
consumption.
ResearchArea Cancer > Tumor biomarkers
Cancer > Type of cancer > Ovarian
Cell Biology > Cell adhesion > Cell-cell adhesion > Leukocyte
GeneTex Inc. All rights reserved. Page 1 of 2
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DATASHEET
Abbexa Ltd, Innovation Centre, Cambridge Science Park, Cambridge, CB4 0EY, UK
Telephone: +44 (0) 1223 755950 - Fax: +44 (0) 1223 755951 - E-Mail: info@abbexa.com
Registered in England: 8475531 - VAT Reg No: GB 167 9240 79
Page 1
PCT (Capture) Antibody
Catalogue No.:abx019247
PCT (Capture) Antibody against Human PCT. PCT is a peptide precursor of the hormone calcitonin, the latter being involved
with calcium homeostasis. It is composed of 116 amino acids and is produced by parafollicular cells (C cells) of the thyroid and
by the neuroendocrine cells of the lung and the intestine. Measurement of procalcitonin can be used as a marker of severe
sepsis caused by bacteria and generally grades well with the degree of sepsis, although levels of procalcitonin in the blood are
very low. PCT has the greatest sensitivity (85%) and specificity (91%) for differentiating patients with systemic inflammatory
response syndrome (SIRS) from those with sepsis, when compared with IL-2, IL-6, IL-8, CRP and TNF-alpha. It is a biomarker
of bacterial infection which may help gauge the severity and prognosis of patients with CAP. In addition to clinical predictors,
PCT may assist in decisions pertaining to timing of discharge from hospital and the discontinuation of antibiotics.
It is recommended to use abx019247 (this product) as the capture antibody and abx019248 as the detection antibody.
Target: PCT
Reactivity: Human
Host: Mouse
Clonality: Monoclonal
Tested Applications: ELISA, WB, CLIA, TIA
Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.
Immunogen: Recombinant PCT protein.
Purity: > 95% by HPLC & SDS-PAGE.
Purification: Protein A or G purified.
Form: Liquid
Isotype: IgG2b
Conjugation: Unconjugated
Specificity: Specifically recognises human PCT.
Storage: Aliquot and store at -20°C for long-term storage. Avoid repeated freeze and thaw cycles.
Buffer: 0.01 M PBS (pH7.4) and 0.15 M NaCl. Does not contain preservatives.
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Product name Recombinant Human C Reactive Protein
Protein length Full length protein
Nature Recombinant
Source HEK 293 cells
Accession P02741
Species Human
Sequence FGQTDMSRKA FVFPKESDTS YVSLKAPLTK
PLKAFTVCLH FYTELSSTRG YSIFSYATKR
QDNEILIFWS KDIGYSFTVG GSEILFEVPE
VTVAPVHICT SWESASGIVE FWVDGKPRVR
KSLKKGYTVG AEASIILGQE QDSFGGNFEG
SQSLVGDIGN VNMWDFVLSP DEINTIYLGG
PFSPNVLNWR ALKYEVQGEV FTKPQLWP
Molecular weight 23 kDa including tags
Amino acids 17 to 224
Tags His tag C-Terminus
Amino Acid Sequence
Applications SDS-PAGE
Endotoxin level < 1.000 Eu/µg
Purity >95% by SDS-PAGE .
Form Lyophilised
Product datasheet
Recombinant Human C Reactive Protein ab167710
1 Image
Overview
Description
Specifications
Our Abpromise guarantee covers the use of ab167710 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1
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Appendix B
Antibody Pairing Test Methodology
The following appendix details the antibody pairing test methodology followed to
determine optimal capture-detection antibody pair. The antibody pairing tests
were conducted at Synexa Life Sciences, Cape Town, over two days. Two diﬀerent
tests were conducted to test the respective antibody pairs - an MSD test was
conducted for the CRP pairing, and an ELISA test was conducted for the PCT
pairing. The following section describes the methodology followed, ﬁrst for the
ELISA tests conducted for the PCT antibody pairings; then for the MSD tests,
conducted for the CRP antibody pairings.
B.1 PCT - Enzyme-linked Immunosorbent Assay
(ELISA) Methodology
B.1.1 ELISA Reagent Preparation
In order to ensure eﬃciency of the test procedure, all reagents were prepared
before commencement of the ELISA testing procedure. The reagent preparation
procedure is listed as follows:
1. Preparation of capture antibodies:
(a) Capture Antibody 1 Dilution (Coating Solution 1): Prepare 1 mL of a
dilution of 1µg/mL anti-PCT Capture Antibody 1 in PBS buﬀer.
(b) Capture Antibody 2 Dilution (Coating Solution 2): Prepare 1 mL of a
dilution of 1µg/mL anti-PCT Capture Antibody 2 in PBS buﬀer.
2. Wash Buﬀer: Prepare 1 L of 0.05 % Tween-20 in PBS buﬀer. e.g. add 0.5
mL of Tween-20 to 999.5 mL PBS.
90
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3. Assay Buﬀer: Prepare 50 mL of 1 wt% BSA (bovine serum albumin) in PBS
buﬀer. e.g. add 0.5 g BSA to 50 mL PBS.
4. Blocking Buﬀer: Prepare 50 mL of 3 wt% BSA (bovine serum albumin) in
PBS buﬀer. e.g. add 1.5 g BSA to 50 mL PBS.
5. Recombinant PCT Protein Dilutions: add here.
6. Biotinylated Antibody Solution: Prepare the biotinylated anti-PCT detec-
tion antibody 1 solution in assay buﬀer according to the Lightning-Linkr
Rapid Biotin Conjugation Kit protocol. In order to ensure suﬃcient anti-
bodies remaining for ﬁnal sensor tests, adjust the solution quantities in the
protocol as advised by Synexa scientist. The adjusted biotinylation pro-
cedure is listed as follows (values in brackets show the originally speciﬁed
quantities):
(a) (Additional step) Allot 40 µL of anti-PCT detection antibody 1 solution.
(b) Add 1 µL of LL modiﬁer reagent per 10 µL of antibody to be labelled
and mix gently. In this case, add 4 µL of LL modiﬁer reagent to the 40
µL of antibody.
(c) (Additional step) Dilute the antibody-modiﬁer sample with 50 µL of
PBS.
(d) Remove the cap from the Lightening-Linkr Rapid mix and pipette the
diluted antibody-modiﬁer sample directly onto the lyophilized material.
Resuspend and re-dispense the liquid gently to mix.
(e) Replace the cap on the vial and leave standing for 30 (15) minutes at
room temperature for incubation. Since the amount of antibody being
conjugated in this step is less than the amount speciﬁedin the original
protocol, double the incubation time (i.e. from 15 to 30 minutes) to
ensure Alternatively, incubate overnight at room temperature. Longer
incubation times do not have a negative eﬀect on the conjugation.
(f) After the incubation, add 1 µL of LL Rapid Quencher reagent for every
10 µL of antibody used. In this case, add 4 µL of LL Rapid Quencher.
(g) The conjugate can be used after 5 minutes and does not require puriﬁ-
cation.
7. Streptavidin-HRP Solution: Prepare a 1/1000 dilution of Streptavidin-HRP
stock in Assay Buﬀer. e.g. add 13µL stock to 12987 µL assay buﬀer.
8. TMB Substrate Solution: Prepare a 1:1 solution of TMB Reagent A and
TMB Reagent B. Note that solutions are light sensitive - therefore keep
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away from light until use. e.g. add 6 mL of TMB Reagent A to 6 mL of
TMB Reagent B.
9. Stop Solution: Prepare 2N HCL Solution
B.1.2 ELISA Test Procedure
Following the preparations of the respective reagents, the ELISA test protocol was
followed. The protocol is listed as follows:
1. Day 1 procedure:
(a) Ensure that both anti-PCT coating solutions (capture antibodies) have
been prepared.
(b) Fill each of the relevant wells with 100 µL of the required anti-PCT
coating solution. Fill the ﬁrst 48 wells with anti-PCT coating solution
1 and the second 48 wells with anti-PCT coating solution 2.
(c) Seal the plate with the plate sealer. Incubate the sealed ELISA plate
overnight, in the dark at 4 ◦C.
2. Day 2 procedure:
(a) Remove ELISA plate from storage place and wash plate three times
with 300 µL/well of wash buﬀer.
(b) Add 300 µL of blocking buﬀer to each well and incubate for at least 90
minutes at room temperature whilst shaking at 350 rpm. Record the
start and end times of the incubation process.
(c) Remove the ELISA plate from the shaker and wash it three times with
300 µL/well of wash buﬀer.
(d) Since two diﬀerent antibody pairs are being evaluated, the 96-well
ELISA plate must be split into two 48-well sections. Two lots of each
diﬀerent recombinant PCT protein dilution must be added to each side
of the ELISA plate. Exactly 100 µL of each dilution must be added per
well. Finally, at the end of the sequence, two wells must be ﬁlled with
100 µL of PBS blank . The layout of the ELISA plate as described is
shown in ﬁgure B.1.
(e) Seal the plate with the plate sealer. Incubate the plate for one hour
at room temperature with gentle shaking at 350 rpm. Record the start
and end times of the incubation process.
(f) Remove the ELISA plate from the shaker and wash it three times with
300 µL/well of wash buﬀer.
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Figure B.1: Schematic showing the 13 diﬀerent dilutions of recombinant PCT
protein and the corresponding layout of the 96-well ELISA plate.
(g) Add 100 µL of biotinylated detection antibody solution to each well.
(h) Seal the plate with the plate sealer. Incubate the plate for one hour
at room temperature with gentle shaking at 350 rpm. Record the start
and end times of the incubation process.
(i) Remove the plate from the shaker and wash three times with 300
µL/well of wash buﬀer.
(j) Add 100 µL streptavidin-HRP solution to each well.
(k) Seal the plate with the plate sealer. Incubate the plate for one hour
at room temperature with gentle shaking at 300 rpm. Record the start
and end times of the incubation process.
(l) Remove the plate from the shaker and wash three times with 300
µL/well of wash buﬀer.
(m) Add 100 µL of TMB substrate to each well.
(n) Incubate the plate without the plate sealer at room temperature whilst
shaking at 350 rpm for up to 30 minutes. Check plate regularly to
ensure that colour does not over-develop.
(o) Add 50 µL/well of stop solution.
(p) Read the plate absorbance at a wavelength of 450 nm.
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B.2 CRP - Meso Scale Discovery (MSD)
Methodology
B.2.1 Reagent Preparation
Meso Scale Discovery (MSD) was used to determine the most suitable capture-
detection pair for the anti-CRP antibodies. Again, all reagents necessary for the
MSD testing process were prepared beforehand. The reagent preparation proce-
dure is listed as follows:
1. Capture Antibody Dilution (Coating Solution): Prepare 1 mL (quantity?)
of a dilution of 1µg/mL anti-CRP Capture Antibody in PBS buﬀer.
2. Wash Buﬀer: Prepare 1 L of 0.05 % Tween-20 in PBS buﬀer. e.g. add 0.5
mL of Tween-20 to 999.5 mL PBS.
3. Assay Buﬀer: Prepare 50 mL of 1 wt% BSA (bovine serum albumin) in PBS
buﬀer. e.g. add 0.5 g BSA to 50 mL PBS.
4. Blocking Buﬀer: Prepare 50 mL of 3 wt% BSA (bovine serum albumin) in
PBS buﬀer. e.g. add 1.5 g BSA to 50 mL PBS.
5. Recombinant CRP Protein Dilutions: add here.
6. Preparation of detection antibodies:
(a) Prepare 2 µg/mL Anti-CRP Detection Antibody 1 solution in assay
buﬀer. e.g. Add 5µL anti-CRP Detection Antibody 1 stock to 2495 µL
assay buﬀer.
(b) Prepare 2 µg/mL Anti-CRP Detection Antibody 2 solution in assay
buﬀer. e.g. Add 5µL anti-CRP Detection Antibody 2 stock to 2495 µL
assay buﬀer.
(c) Prepare 2 µg/mL Anti-CRP Detection Antibody 3 solution in assay
buﬀer. e.g. Add 5µL anti-CRP Detection Antibody 3 stock to 2495 µL
assay buﬀer.
7. Anti-mouse SULFO-TAG Solution: Prepare goat anti-mouse SULFO-TAG
antibody solution in assay buﬀer. e.g. Add 8 µL goat anti-mouse SULFO-
TAG labelled antibody stock solution to 3992 µL assay buﬀer.
8. Read Buﬀer: Prepare MSD Read Buﬀer T in distilled water. e.g. Add 10
mL MSD Read Buﬀer T to 10 mL of dH2O.
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B.2.2 MSD Test Procedure
Following the preparations of the respective reagents, the MSD test protocol was
followed. The protocol is listed as follows:
1. Day 1 procedure:
(a) Ensure that the anti-CRP coating solution (capture antibody) has been
prepared.
(b) Fill each of the 96 wells with 25 µL of the required anti-CRP coating
solution.
(c) Seal the plate with the plate sealer. Incubate the sealed MSD plate
overnight, in the dark at 4 ◦C.
2. Day 2 procedure:
(a) Remove MSD plate from storage place and wash plate three times with
300 µL/well of wash buﬀer.
(b) Add 200 µL of blocking buﬀer to each well and incubate for at least two
(2) hours at room temperature whilst shaking at 350 rpm. Record the
start and end times of the incubation process.
(c) Remove the MSD plate from the shaker and wash it three times with
300 µL/well of wash buﬀer.
(d) Add 25 µL of blanks (PBS) and the prepared sample solutions to each
of the relevant wells. Since there are three diﬀerent antibody pairings,
add the sequential dilutions to each third of the plate. The layout of
the MSD plate as described is shown in ﬁgure B.2.
(e) Seal the plate with the plate sealer. Incubate the plate for one hour
at room temperature with gentle shaking at 350 rpm. Record the start
and end times of the incubation process.
(f) Remove the MSD plate from the shaker and wash it three times with
300 µL/well of wash buﬀer.
(g) Add 25 µL of detection antibody solution to each relevant well. There
are three diﬀerent detection antibody solutions, therefore
(h) Seal the plate with the plate sealer. Incubate the plate for one hour
at room temperature with gentle shaking at 350 rpm. Record the start
and end times of the incubation process.
(i) Remove the plate from the shaker and wash three times with 300
µL/well of wash buﬀer.
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Figure B.2: Schematic showing the 13 diﬀerent dilutions of recombinant CRP
protein and the corresponding layout of the 96-well MSD plate
(j) Add 100 µL streptavidin-HRP solution to each well.
(k) Seal the plate with the plate sealer. Incubate the plate for one hour
at room temperature with gentle shaking at 300 rpm. Record the start
and end times of the incubation process.
(l) Remove the plate from the shaker and wash three times with 300
µL/well of wash buﬀer.
(m) Add 100 µL of TMB substrate to each well.
(n) Incubate the plate without the plate sealer at room temperature whilst
shaking at 350 rpm for up to 30 minutes. Check plate regularly to
ensure that colour does not over-develop.
(o) Add 50 µL/well of stop solution.
(p) Read the plate absorbance at a wavelength of 450 nm.
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Appendix C
Output Curves of the Four OECT
Iterations
The following appendix shows the output characteristics of selected transistors
from the ﬁrst three OECT iterations. Output characteristics are obtained by
sweeping the drain voltage for diﬀerent sequential gate voltages, as shown in the
example ﬁgure C.1.
Figure C.1: Example plot of an output sweep
97
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C.1 Iteration 1: All Printed OECT Layout
An example output curve from the ﬁrst iteration of OECTs is shown in ﬁgure ??.
To demonstrate their deterioration over time, the drain current is plotted against
samples (time) in ﬁgure E.6
Figure C.2: Example output characteristics from the ﬁrst iteration
Figure C.3: Loss of functionality due to PBS seepage into paper
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C.2 Iteration 2: Addition of Photoresist Coating
Figure C.4: Example output characteristics from the second iteration
Figure C.5: Deterioration of the OECT over time due to PEDOT:PSS breakdown
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C.3 Iteration 3: Addition of Immersed Gate and
Increased Amount of PEDOT:PSS Layers
For the third iteration, the sweep conditions were changed to include a forward
and backward sweep on the drain voltage. Furthermore, in the example sweep
shown here, the gate voltage was stepped in a positive direction, which should
cause a corresponding decrease in drain current.
Figure C.7 shows the output characteristics corresponding to the sweep condi-
tions shown in ﬁgure C.6. Figure C.8 shows the drain and gate current over the
sweep time period.
Figure C.6: Sweep conditions for the output curves given below, showing the
forward and reverse drain voltage sweeps for increasing gate voltage steps.
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Figure C.7: Example output characteristics from the third iteration
Figure C.8: Drain (blue) and gate (red) current over the sweep time period. The
gate current clearly dominates, contributing to the measured drain current.
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C.4 Iteration 4: Addition of 5 µL Drop of
PEDOT:PSS Semiconductor and Widening
of the Channel
Figure C.9: Sweep conditions for the output curves given below, showing the
forward and reverse drain voltage sweeps for increasing gate voltage steps.
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Figure C.10: Output characteristics from the ﬁrst OECT of the fourth design
iteration.
Figure C.11: Drain (blue) and gate (red) current over the sweep time period. The
gate current was clearly suppressed in comparison to the third iteration.
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Appendix D
Characteristics of Diﬀererent
OECTs
D.1 OECT 1
Figure D.1: OECT 1 output characteristics.
104
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Figure D.2: OECT 1 transfer characteristics.
D.2 OECT 2
Figure D.3: OECT 2 output characteristics.
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Figure D.4: OECT 2 transfer characteristics.
D.3 OECT 3
Figure D.5: OECT 3 output characteristics.
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Figure D.6: OECT 3 transfer characteristics.
Stellenbosch University  https://scholar.sun.ac.za
Appendix E
LabVIEW Programs
E.1 Constant DC Output Program
Figure E.1: Block diagram of the constant DC output program.
108
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E.2 Transfer Curve Sweep Program
Figure E.2: Block diagram of the transfer sweep program.
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Figure E.3: Block diagram of the transfer sweep program continued.
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E.3 Output Curve Sweep Program
Figure E.4: Block diagram of the output curve sweep program.
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Figure E.5: Block diagram of the output curve sweep program continued.
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Figure E.6: Virtual interface (VI) of the LabVIEW programs.
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Appendix F
Antibody Immobilisation and
Reagent Preparation
The following appendix brieﬂy describes the methodology followed for the immo-
bilisation of the capture antibodies as well as the reagent preparation for ﬁnal
testing.
F.1 Antibody Immobilisation Methodology
The capture antibody immobilisation method is identical for both CRP and PCT,
and is listed as follows:
1. Prepare the streptavidin reagent at a concentration of 20 µg/mL in PBS.
2. Add 20 µL of streptavidin reagent to the well of each sensor. Pipette up and
down to mix gently.
3. Cover wells and incubate for 24 hours at four degrees Celsius.
4. Take the sensors out and wash each well three times with 20 µL of PBS.
5. Biotinylate the capture antibodies according to the Lightening-Link Biotiny-
lation Kit protocol.
6. Prepare the biotinylated capture antibody reagent in assay buﬀer at a con-
centration of 10 µg/mL.
7. Fill each well with 20 µL biotinylated capture antibody reagent. Pipette up
and down to mix gently.
8. Cover wells and incubate at four degrees Celsius for two hours.
114
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9. Wash each well three times with 20 µL of PBS.
The capture antibodies were then successfully immobilised to the sensor substrate
and the sensors were ready to test.
F.2 Reagent Preparation for Final Testing
The detection antibody reagent as well as the recombinant protein dilutions were
prepared in the same way for both CRP and PCT. Each respective procedure is
detailed below.
F.2.1 Detection Antibody Reagent
The following simple process was followed for the preparation of detection antibody
reagents:
1. Dilute the stock antibody to a concentration of 100µg/mL in the gold nanopar-
ticle conjugate modiﬁer.
2. Follow the gold nanoparticle conjugation kit protocol.
3. Dilute the resulting conjugate reagent in PBS to a concentration of 10
µg/mL.
The AuNP-labelled detection antibody was then ready for testing.
F.2.2 Recombinant Protein Dilutions
The following protocol was followed to prepare the necessary recombinant protein
dilutions:
1. Dilute the stock proteins in PBS to a concentration of 1 mg/mL.
2. Dilute further to the required starting concentration using PBS.
3. Take half of the ﬁrst dilution and add it to a matching volume of PBS. This
will half the concentration of the recombinant protein reagent.
4. Repeat step four until required concentration is reached.
The respective protein dilutions were then ready for testing.
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Biomarker Categories
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Table G.1: Diﬀerent Biomarker Categories and Descriptions (adapted from the
BEST Resource [7])
Biomarker Category Description
Diagnostic Biomarker A biomarker used to detect or conﬁrm pres-
ence of a disease or condition of interest or to
identify individuals with a subtype of the dis-
ease.
Monitoring Biomarker A biomarker measured serially for assessing
status of a disease or medical condition or for
evidence of exposure to (or eﬀect of) a medical
product or an environmental agent.
Pharmacodynamic Biomarker A biomarker used to show that a biological re-
sponse has occurred in an individual who has
been exposed to a medical product or an envi-
ronmental agent.
Predictive Biomarker A biomarker used to identify individuals who
are more likely than similar individuals with-
out the biomarker to experience a favourable
or unfavourable eﬀect from exposure to a med-
ical product or an environmental agent.
Prognostic Biomarker A biomarker used to identify likelihood of a
clinical event, disease recurrence or progres-
sion in patients who have the disease or med-
ical condition of interest.
Safety Biomarker A biomarker measured before or after an expo-
sure to a medical product or an environmental
agent to indicate the likelihood, presence, or
extent of toxicity as an adverse eﬀect.
Susceptibility/ Risk Biomarker A biomarker that indicates the potential for
developing a disease or medical condition in an
individual who does not currently have clini-
cally apparent disease or the medical condi-
tion.
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